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Abstract	  
In the past few decades there has been an increasing awareness of pharmaceuticals in the 
environment and pharmaceuticals as environmental pollutants. Pharmaceuticals find their way 
to the aquatic environment mostly through sewage treatment plants. The potential toxicity of 
pharmaceuticals is of great interest as they have been discovered in air, water, soil, sediment 
and biota.  
 
The aim of the thesis was to investigate the stability of selective serotonin reuptake inhibitors 
(SSRIs) in seawater. This was achieved by looking at the degradation of SSRIs in filtered 
seawater containing the marine diatoms S. marinoi and A. longicornis in monocultures.  
It was desirable to have a natural environment, and this was achieved by regulating 
parameters including light and temperature.  
 
Liquid-phase microextraction (LPME) was used to extract and quantify the SSRIs, while ultra 
performance liquid chromatography coupled with a tandem mass spectrometry (UPLC-
MS/MS) was used to analyze the samples. 
 
This thesis showed that there was a difference in degradation of the SSRIs between the two 
monocultures of S. marinoi and A. longicornis. The experiment containing the diatom S. 
marinoi had a higher decrease in the average measured concentration for fluoxetine, 
fluvoxamine, paroxetine and citalopram than the A. longicornis experiments. Fluoxetine and 
fluvoxamine were the least stable SSRIs. For the first 7 days of the S. marinoi experiment, 
fluoxetine had a decrease of 95%, while fluvoxamine had a decrease of 99.5%, while 
fluvoxamine had a decrease of 87% from day 2 to day 9, in the A. longicornis experiment.  
 
The Stockholm County Council classifies Sertraline as a moderate environmental risk, which 
is the highest environmental risk given to any of the SSRIs. In this study sertraline had a 
slower degradation in the average measured concentration compared to fluoxetine and 
fluvoxamine, but it was not as stable as Citalopram. 
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1. Introduction  
1.1 Pharmaceuticals in the Environment 
1.1.1 Pharmaceuticals in the Environment – a Perspective 
Reports from the Arctic Monitoring and Assessment Program (AMAP), the Stockholm 
Convention on Persistent Organic Pollutants, the European Unions “Regulation on 
Registration, Evaluation, Authorization and Restriction of Chemicals” (REACH), and the 
United States Environmental Protection Agency (EPA) recognize several pollutants as a 
global problem. Persistent organic pollutants (POPs), polyaromatic hydrocarbons (PAHs), 
pharmaceuticals and personal care products (PPCP), metals and radioactive substances are a 
few groups of these pollutants which are viewed as problematic and need to be investigated. 
 
Tabak and Bunch (1) expressed a concern for hormones, both natural and synthetic, not being 
easily biodegradable in the environment already in 1970. The Food and Drug Administration 
(FDA) has since 1980 required an assessment on the environmental risks for veterinary 
medicine. In the late 1990s the European Union set requirements for ecotoxicology testing of 
pharmaceuticals (2, 3).  
 
Human pharmaceuticals make their way to the environment in different ways, and the most 
common way is through excretion after normal usage where both the drug and its metabolites 
may be excreted. Unused drugs might be flushed down the drain or the toilet, or thrown away 
with household waste. Through these ways pharmaceuticals then may enter the sewage 
system and end up in the aquatic environment (2, 4, 5).  Figure 1 (6) gives an overview of 
how pharmaceuticals may enter the environment and be distributed to air, water, soil and 
sediment (3). 
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Figure 1: The different ways prescription drugs may enter the environment. Used with 
permission from Terje Vasskog (6). 
 
In a report from 2010 published by the Norwegian Ministry of Environment (now: Ministry of 
Climate and Environment) (7) acknowledging the problem of pharmaceuticals as en 
environmental pollutant. They state that there are gaps in the current knowledge concerning 
pharmaceuticals in the environment, and that environmental risk assessments would not be 
crucial for the benefit/risk assessment of pharmaceuticals. 
 
Sweden started their environmental classification of pharmaceuticals in 2004, and the first 
results were published in 2005. The environmental classification is based on toxicity, 
bioaccumulation of a given pharmaceutical and a ratio between the predicted environmental 
concentration (PEC) and the predicted no effect concentration (PNEC) for that 
pharmaceutical. The PNEC is individual for the species in question. A pharmaceutical with an 
insignificant risk for the environment has a PEC/PNEC ratio of less than 0.1, while a 
pharmaceutical with a high environmental risk factor has a ratio larger than 10 (8). The 
Organization for Economic Co-operation and Development (OECD) has a number of test 
guidelines that may be used when looking at the environmental risk of chemicals and 
pharmaceuticals, the criteria of which the Swedish environmental classifications use (9). 
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Pharmaceuticals are made to produce a biological effect and have properties, for example 
being lipophilic and being able to bind to other molecules and yield cellular effects, which 
make them susceptible to bioaccumulation in the environment and possible harmful effects 
(10, 11). The general focuses of the environmental toxicology studies are the potentially 
negative effects that the pharmaceuticals might have on non-target organisms, for example 
algae, zooplankton or fish (2, 3, 8). Most of the studies say something about the acute 
toxicology of the pharmaceuticals and has a focus on mortality as an endpoint for the 
environmental risk assessments, and the concentrations in these studies are often higher than 
the concentrations found in the environment. As there is a continuous release of low 
concentrations of pharmaceuticals into the environment, the risk of acute toxicity is low, but 
the pharmaceuticals may be present at all times. Both aquatic and terrestrial organisms may be 
exposed to these low concentrations over longer periods of time (2, 3).  
 
Webb (12) conducted a meta-analysis (2001) where he listed environmental risk assessments, 
both acute and chronic, of pharmaceuticals on aquatic organisms. He suggests that algae are 
the most sensitive of the marine species when exposed to pharmaceuticals in acute toxicology 
studies. Antidepressants were mentioned as one of the most ecotoxic pharmaceuticals. Among 
the pharmaceuticals that had acute effects below 1 mg/L were fluoxetine and fluvoxamine. 
Fluoxetine had a median effective concentration of 0.031 mg/L for unspecified green algae, 
while fluvoxamine had a lowest observed effective concentration of 0.003 mg/L for the fresh 
water clam Sphaerium striatinum. In the chronic ecotoxicology data from this study, a no-
observed effect concentration of 0.001 mg/L for fluoxetine and 31 mg/L for fluvoxamine was 
found for unspecified green algae. He concluded that there was a focus on the acute endpoint 
lethality, and there were only 20 pharmaceuticals with chronic risk assessments. One does not 
yet know a lot about the chronic effects pharmaceuticals might have, as studies on 
multigenerational lifecycles are rarely conducted.  
 
Another weakness of the environmental risk studies on pharmaceuticals is that they manly 
focus on just one pharmaceutical and its effect on organisms, even though all pharmaceuticals 
that are distributed through a waste water treatment plant will always come as a mixture, and 
may create a “cocktail effect” in aquatic organisms (13). Brooks et al (14) found fluoxetine, 
sertraline, and their metabolites norfluoxetine and desmethylsertraline in brain, liver and 
muscle tissues of several types of fish in the Pecan Creek and Clear Creek streams in Texas, 
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United States. This indicates that the “cocktail effect” of pharmaceuticals in the environment 
is a fact and it should be investigated further in addition to the chronic effects of 
pharmaceuticals. 
 
Even though pharmaceuticals have been released to the environment for a long time, it is only 
in the recent years, due to the continuous improvement of knowledge, measurement and 
analyzing methods, that one has been able to quantify them from environmental samples. The 
quantification of pharmaceuticals in the environment is usually done with liquid-phase 
chromatography (LC) and tandem mass spectrometry (MS/MS) (2, 3). 
 
1.1.2 Pharmaceuticals in the Norwegian Environment 
Northern Europe has been suggested to be among the more sensitive areas in Europe towards 
exposure of man-made pollutants, including pharmaceuticals, due to daylight and temperature 
conditions, and demographics. Because of the seasonal daylight conditions, with light for up 
to 24 hours in the summer and the absence of daylight in winter, the photochemical 
degradation of some pollutants will necessarily be impacted. There are overall lower 
temperatures in northern Europe than in central Europe, which may lead to lower 
biodegradation and extended half lives for some pharmaceuticals. Typical for Scandinavian 
demographics are the smaller, scattered settlements where modern sewage treatment plants 
(STP) are not affordable. This results in the release of certain pharmaceuticals in to the 
environment without the necessary sewage treatment being performed (15).  
 
A study conducted in Tromsø by Weigel et al (16) in 2004 showed high amounts of several 
pharmaceuticals, caffeine and the insect repellent N,N-dietyl-meta-toluamid (DEET) in 
sewage samples and seawater samples. They found traces of ibuprofen and its metabolites 
hydroxyl-ibuprofen and carboxy-ibuprofen, diclofenak, triclosan, metoprolol, propranolol and 
SSRIs. Traces of SSRIs have been found in STPs in Longyearbyen, Tromsø and Oslo (17, 
18). 
 
Schlabach et al (19) did a non-target screening in 2013 for several types of pollutants from 
different environmental samples from Norway. This resulted in the detection of 4395 
substances where 1476 of these were identified. Among these were several phthalates, PAHs 
and PPCPs such as diethylhexylphthalate, fluoranthene and lovastatine respectively. 
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1.1.3 General Use of Pharmaceuticals in Norway 
Since 1977 the Norwegian Institute of Public Health has published statistics of drug 
consumption in Norway (20). Data of drug consumption in Norway from 2004 has been 
available for the public in an online database, “Reseptregisteret”, since 2004. Very few 
countries have publications or databases that can give statistics on drug consumption, and 
therefore there are no available data on the total amount of pharmaceuticals used in the world, 
and the consumption of pharmaceuticals differ from country to country (21).   
For pharmaceuticals with marketing authorization sold from pharmacies, hospitals, nursing 
homes and non-pharmacy outlets in Norway in 2013 totaled 13.6 billion Norwegian kroners 
(NOK) with an estimated retail cost of about 20.0 billion NOK (20). From 2004 to 2013 the 
sales of pharmaceuticals, excluding veterinary medicine, have increased with 39%, from 1.62 
billion defined daily dosages (DDD) to 2.25 billion DDD in Norway (20). The amount of 
pharmaceuticals sold may give us an indication of the amount of pharmaceuticals in the 
environment. 
For antidepressants (N06A), the total sale was 288 million NOK, or about 98 million defined 
daily dosages (DDD) in 2013 (22). Today there are a number of antidepressants on the 
Norwegian market. Table 1 summarizes the different groups of antidepressants by the 
anatomical therapeutic chemical (ATC) classification system and the DDD per 1000 
inhabitants per day sold in 2013. Of the antidepressants, the SSRIs were the most sold 
antidepressants based on DDD per 1000 inhabitants per day. The total sales of SSRIs (N06A 
B) in NOK was 150 million, or 65 million DDD in 2013 (23). The World Health Organization 
(WHO) defines DDD as ”the assumed average maintenance dose per day for a drug used for 
its main indication in adults” (24). 
Table 1: The DDD per 1000 inhabitants per day sold of antidepressants based on anatomical 







ATC Antidepressants DDD/1000 inhabitants/day  
N06AA Non-selective monoamine 
reuptake inhibitors 3.48 
N06AB SSRI 37.47 
N06AG Monoamine oxidase 
inhibitors 0.15 
N06AX Other antidepressants 15.55 
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Figure 2 gives an overview of the number of users of SSRIs per 1000 inhabitants per year 
from 2004 until 2013. From this illustration one can see that the use of SSRIs has been stable 
since 2004 when it comes to users per 1000 inhabitants per year.  
 
 
Figure 2: The number of users of all ages of SSRIs (N06A B) in Norway (25). 
 
1.1.4 Selective Serotonin Reuptake Inhibitors 
Of the affective disorders, depression is one of the most common. The main theory behind 
depression is the monoamine theory presented by Schildkraut in 1965 (11). It is based on the 
effect that some drugs have on monoamines. For example, reserpine may cause depression by 
reducing the amount of noradrenaline and serotonin (5-HT) in the brain. Antidepressants such 
as tricyclic antidepressants (TCAs) and other non-selective monoamine reuptake inhibitors 
block the reuptake of these substances which in turn increases the amount of these in the brain 
(11, 26). Although the actions and effects of these drugs support the theory, there are no 
pharmacological evidence that can draw a distinct line between the lack of monoamines and 
depression after biochemical studies in depressed patients (11). 
 
SSRIs work by selectively inhibiting the serotonin (5-HT) uptake in the nerve synapse in the 
brain. This selectivity to one monoamine, unlike for example TCA, gives less severe adverse 
effects and a lower risk of overdose (11).  
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Today there are six SSRIs on the Norwegian market. The first SSRI on the Norwegian market 
was fluvoxamine (1990). Paroxetine followed in 1993, and then citalopram (1995), sertraline 
(1996), fluoxetine (1997) and escitalopram, the S-enantiomer of citalopram, (2002) were 
marketed. The marketing dates may be found in the summary of product characteristics (SPC) 
for each respective SSRI on the webpages for the Norwegian Medicines Agency 
(www.legemiddelverket.no). Table 2 summarizes the sales of these SSRIs in NOK, DDD and 
kilograms (kg) in 2013 in Norway (27). 
 
Table 2: The sales in NOK, DDD and for all the SSRIs individually based on ATC-code in 2013 in 
Norway (27). 
ATC SSRI Sales in NOK Sales in DDD Total sale kg 
N06AB03 Fluoxetine  15,463,494 3,790,935 76 
N06AB04 Citalopram 16,570,791 8,152,222 163 
N06AB05 Paroxetine  14,261,411 5,297,402 106 
N06AB06 Sertraline 29,464,176 12,594,441 630 
N06AB08 Fluvoxamine 1,009,849 171,014 17 
N06AB10 Escitalopram  73,437,376 35,096,512 702 
 
 
The Stockholm County Council (28) has made a list of the environmental risks of the  
pharmaceuticals they have assessed so far. The environmental risk assessment is based on 
bioaccumulation, persistence and possible toxicity for aquatic organisms. For the SSRIs they 
state that sertraline has a moderate environmental risk, while fluoxetine has a low 
environmental risk. Fluvoxamine has an insignificant environmental risk, and for paroxetine, 
citalopram and escitalopram an environmental risk cannot be excluded because the 
documentation is insufficient. These risk assessments are based on data from Sweden, and 
they might not apply for other countries. Different consumption patterns for pharmaceuticals, 
different types of STPs (biodegradation or sewage sludge), and where in the environment the 
pharmaceuticals end up will differ from country to country. 
 
Johnson et al (29) looked at the toxicity of the SSRIs citalopram, paroxetine, sertraline, 
fluoxetine and fluvoxamine for the algae Pseudokirchneriella subcapitata, Chlorella vulgaris, 
Scenedesmus acutus, and S. quadricauda. For the growth inhibition sturdy they looked at PEC 
and PNEC to determine the acute growth inhibition toxicity in 96 hours. Sertraline turned out 
to be the most toxic of the SSRIs with growth inhibition occurring at 4.57 µg/L, closely 
followed by fluoxetine (31.34 µg/L) and fluvoxamine (1662.91µg/L). 
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1.1.5 Diatoms 
Microalgae are important primary producers and from the foundation of marine food webs. 
Diatoms are eukaryotic, unicellular microalgae, and dominate the marine phytoplankton 
communities (30-32). There are two main shapes of diatoms: Centrics and Pennates. The main 
difference between them is the sculpting of the frustule, a highly evolved silicate cell wall, 
which consists of two valves, one overlapping the other. Diatoms have enzymatic pathways 
for uptake of nutrients such as nitrogen, phosphorus and iron; and they also use endocytosis 
and exocytosis for uptake of organic matter.  One distinct feature of diatoms is their large 
vacuole, where they may store nutrients or use to regulate buoyancy. Diatoms also have a 
biochemical defense mechanism. They are capable of releasing allelopathic compounds such 
as fatty acids that are enzymatically turned into unsaturated aldehydes (33). 
 
Diatoms may be found in a number of aquatic habitats for example marine, fresh water, polar 
or tropic habitats, and even in soil. This is due to their ability to acquire new traits for the 
different habitats. Morphology has been the main method of identifying diatoms, but in later 
years, the possibility, and the improvement of techniques, of looking at deoxyribonucleic acid 
(DNA) has given the indication that there is large species diversity, and that most diatoms are 
more likely not to be cosmopolitan, but confined to their habitat (33, 34). There are 
discussions on the number of species of diatoms, and Guiry (35) bluntly estimated in 2012 
that there are about 12,000 discovered species of diatoms and about 8,000 species that 
remains to be discovered. Others estimate that there are about 200,000 different species of 
diatoms (34, 35). 
 
Through asexual reproduction by cell division, some species may divide up to twice per day, 
producing up to 4 million cells in 3 weeks. Favorable conditions for diatom growth include 
the presence of nutrients and light (36). When conditions are unfavorable for the diatoms, 
they form resting spores that can be germinated when conditions are favorable again (37). 
Such life history strategies are common in temperate and arctic waters (38). 
 
During the winter months in the northern seas there are almost no diatoms present (39). A low 
phytoplankton biomass was observed by Degerlund and Eilertsen (40) during the pre-bloom. 
When the day length increases in spring and optimal light conditions are achieved as well as 
an up-welling of resting spores from the sediment and the mixing of nutrients, a spring bloom 
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is initiated. In northern waters, the spring bloom of phytoplankton take place in March-April, 
with a peak bloom in mid-April as the daylight length increases (37, 38, 41). Eilertsen and 
Frantzen (42) showed a significant linear correlation between spring bloom biomass and day 
length. 
 
Skeletonema marinoi (S. marinoi) and Attheya longicornis (A. longicornis) are both centric 
diatom species. The S. marinoi (Figure 3) cells are about 2-12 µm in diameter, and each cell 
may contain 1 or 2 chloroplasts. They have external projections with flared ends. These can 
overlap with the external projections of other S. marinoi, forming chains (43). S. marinoi is 
found along the northern European coast from April-July (44), and blooms in March and 
April (40). A. longicornis cells are about 4-6 µm in diameter with 1-2 chloroplasts in each 
cell. They have four horn-like setae that are about 8-10 times their cell length. A. longicornis 
is found in northern cold to temperate waters and in the Sea of Japan, though the 
biogeographical information relating to this species is limited (45, 46).   
 
Figure 3: Skeletonema marinoi. Photo used with 
permission by the Plankton lab at the Institute for Arctic 
and Marine Biology. 
 
 
Figure 4: Attheya longicornis. Photo used with 
permission by the Plankton lab at the Institute for Arctic 
and Marine Biology. 
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1.2 Extraction-, Separation, and Detection Techniques  
1.2.1 Liquid-Phase Microextraction 
The hollow fiber liquid-phase microextraction (LPME) developed by Pedersen-Bjergaard and 
Rasmussen (47) in 1999 is based on two techniques: the first LPME technique and the 
supported liquid membrane (SLM) technique. The first LPME technique involved the passive 
diffusion of the analyte from the aqueous sample in to a drop of organic solvent. The SLM 
technique was based on the extraction of the aqueous phase with the analyte through a sheet 
of supported liquid membrane with the acceptor phase on the other side of the membrane. 
LPME has since then been developed and may now be applied to numerous analytes (48).  
 
LPME is the extraction of an analyte from an aqueous sample, through an organic phase and 
into the acceptor phase. If the analyte is either acidic or basic, the aqueous solution is pH-
adjusted so that the analyte is not ionized. The hollow fiber is dipped into an organic solution 
that fills the pores of the fiber wall and forms a SLM. The lumen of the fiber is then filled 
with an acceptor phase (48).  
 
LPME may be done in either a 2-phase or a 3-phase extraction. In a 2-phase extraction both 
the pores and the lumen of the hollow fiber are filled with an organic solvent. In a 3-phase 
extraction the pores of the hollow fiber are filled with an organic solvent, while the lumen is 
filled with an aqueous solution. The aqueous solution that fills the lumen is pH-adjusted and 
may be either acidic, if the analyte is basic, or alkaline, if the analyte is acidic. This is to 
ionize the analyte so that it is trapped in the acceptor phase. The sample is also pH-ajusted so 
that the analyte is neutral. The fiber is then stirred in the aqueous solution containing the 
analyte. The analyte passes through the SLM and into the lumen of the hollow fiber through 
passive diffusion (48). This is illustrated in Figure 5. 
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Figure 5: This figure illustrates the LPME method described above with an alkaline 
analyte. The illustration is used with permission by Terje Vasskog (49). 
 
1.2.2 Ultra Performance Liquid Chromatography 
Chromatography is a method for separating analytes. The analytes are separated based on 
their interaction with a stationary and a mobile phase, and identified by using one or more of 
several identification techniques like UV-absorbance, retention time and/or mass 
spectrometer. The analytes that have a high affinity to the mobile phase will have a shorter 
retention time than those that have more affinity to the stationary phase (50).  
 
In high performance liquid chromatography (HPLC) the analytes are injected into to the liquid 
mobile phase and then pumped through a column that is packed with a stationary phase. The 
analyte interacts with the stationary phase, and will thereafter be detected by an appropriate 
detector (50).  
 
Ultra performance liquid chromatography (UPLC) is a further development of HPLC. The 
UPLC uses a smaller particle size in the stationary phase, and the UPLC column often has a 
smaller inner diameter than the HPLC column. This means that the pumps that pump the 
mobile phase through the column must be able to withstand a higher pressure, which is true 
for the UPLC. The smaller particle size and the smaller inner diameter in the UPLC columns 
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1.2.3 Electrospray Ionization 
Electrospray ionization (ESI) is an atmospheric ionization technique often used with UPLC 
coupled with mass spectrometry as a detector.  
 
The mobile phase from the UPLC goes through a steel capillary to which voltage is applied. 
This forms an aerosol spray where the analytes in the aerosol droplets are ionized. A nebulizer 
gas (usually N2) evaporates the liquid in the droplets. Depending on whether the ionization is 
positive or negative, protonated [M+H]+ or deprotonated [M-H]- analytes are formed. 
Depending on the analyte and matrix other ions might also be formed, such as sodium adducts 
in the positive ionization [M+Na]+. The charged analytes are then guided to the mass 
spectrometer by different ion guides for separation and detection. ESI is a soft ionization 
technique, which means that the ions formed are rarely fragmented (53, 54).  
 
1.2.4 Tandem Mass Spectrometer 
The mass spectrometer is a detection method that separates ions by making use of the ions 
mass/charge ratio (m/z). The tandem mass spectrometer (MS/MS) consists of two quadrupoles 
with a collision cell between them. One quadrupole consists of four metal rods that are placed 
parallel to one another and given an electrical field with a combination of alternating current 
(AC) and direct current (DC). Because of the combination of AC and DC and the fact that 
these may be set to particular values with alternating voltages, only ions with specific m/z 
ratios may pass through (53-55). 
 
The collision cell may consist of hexa – or octapoles, or other types of ion guides such as a T-
wave collision cell found in some newer instruments from Waters. In the collision cell a gas, 
often N2 or Ar, fragments the precursor ion by increasing the internal energy of the precursor 
ion through collision until the weakest bonds brake in the precursor ion and product ions are 
formed (53, 54).  
 
Figure 6 gives an overview of an ESI-MS/MS instrument. 
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1.3 Aim of the Thesis 
The aim of this thesis was to investigate the stability of selective serotonin reuptake inhibitors 
(SSRIs) in seawater. This was achieved by looking at the degradation of SSRIs in filtered 
seawater containing the marine diatoms S. marinoi and A. longicornis in monocultures.  
It was desirable to have a natural environment, and this was achieved by regulating 
parameters including light and temperature.  
 
Liquid-phase microextraction (LPME) was used to extract and quantify the SSRIs, while ultra 
performance liquid chromatography coupled with a tandem mass spectrometry (UPLC-
MS/MS) was used to analyze the samples. 
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2. Materials and Methods 
2.1 Chemicals 





dichlorphenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphytalamine) were purchased from Toronto 





1-naphthalenamine) and citalopram-D6, fluoxetine-D5, rac-trans-paroxetine-D4 and 
sertraline-D3 were also purchased from TRC. Figure 7 shows the structures, Pka-values and 
the monoisotopic mass for the SSRIs and their metabolites. 
 
Attheya longicornis (A. longicornis) was isolated 09.03.07 from sediment samples collected in 
Rjipfjorden under the first spring bloom. The Art ID used at the Institute for Arctic and 
Marine Biology (AMB) is AMB 20.2. Skeletonema marioni (S. marioni ) was isolated 
01.12.08 from water samples collected in Håkøybotn. The Art ID for S. marinoi used at AMB 
is AMB 86. They were both used in monocultures and cultivated in a silica mass-cultivating 
medium at AMB at the University of Tromsø. 1 liter (L) of the silica mass-cultivating 
medium contained 0.25 mL Substral from Scotts Celaflor GmbH &Co. KG (Mainz, 
Tyskland), 1 mL silicate solution and 1 µL earth extract both made at the laboratory at the 
Institute for Arctic and Marine Biology at the University of Tromsø (see Appendix	  1 for the 
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Citalopram 









































Monoisotopic mass= 329.14 
Pka= 10.32 
 
Figure 7: Structures, Pka-values (18) and monoisotopic mass of the SSRIs and their metabolites. The structures are 
drawn in ChemDraw. Monoisotopic mass was calculated by using a mass calculator by Christoph Gohlke(57). 
 
Two different mixtures of growth medium were used. The growth medium used in the glass 
beakers with A. longicornis was 0.25 mL/L Substral from Scotts Celaflor GmbH & Co. 
(Mainz, Germany) and 1 mL/L silica mass-cultivating medium as mentioned before. For the 
glass beakers containing S. marioni, the growth medium used was 4 mL/L Guillard ́s f/2 
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mass-cultivating medium from Sigma-Aldrich as well. 
In the fluorometer method, ethanol 70% and HCl 10% was used, both purchased from Sigma-
Aldrich.  
 
For the LPME method ethanol absolute from VWR BDH Prolabo (Leuven, Belgium) sodium 
hydroxide pellets from VWR BDH Prolabo and Merck KGaA (Darmstadt, Germany), 
dihexylether purum ≥ 97% (GC) from Fluka Sigma-Aldrich Chemie GmBH (DHE, 
Steinheim, Germany), formic acid 98-100% for analysis from Merck, and water obtained 
from a Rios 100 MilliQ purification unit from EMD Millipore Corporation (Billerica, MA, 
USA) were used.  
 
Mobile phases used for UPLC were acetonitrile hyper grade for LC-MS from Merck KGaA, 
acetonitrile LC-MS grade for HPLC from VWR BDH Prolabo, formic acid 98-100% for 
analysis from Merck and MilliQ water. Argon (Ar) 4.0 from AGA (Oslo, Norway) was used 
as collision gas in the mass spectrometer. The nebulizer gas used was nitrogen (N2) from a 
NM32LA generator from Peak Scientific (North Billerica, Ma, USA). 
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2.2 Materials and Method Development 
Figure 8 is an illustration of the method set up for this thesis. The algae used are the diatoms 
S. marinoi and A. longicornis. Chl a analysis and extractions were conducted for each 
experiment, but not simultaneously. The experiment was conducted at AMB and Norut. 
 
Figure 8: Schematic illustration of the method proceedings of Chl a analysis and extraction. “Beaker” refers to one 
parallel in one experiment, i.e. there are 3 10 L glass beakers for each experiment. 
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2.2.1 Set Up for Samples with Algae and SSRIs 
This part of the experiment was carried out at AMB. 
To establish the concentration of algae in each culture 2 mL four-well Nunc counting 
chambers from Apogent (Roskilde, Danmark) and a Zeiss Primo Vert microscope from Carl 
Zeiss AG (Oberkochen, Germany) were used. The algae were counted and the concentration 
in cells per liter was calculated. The appropriate amount of algae was then added to each 
beaker (Table 3). 
Table 3: The amount of algae added to each experiment given in 
cells per liter (L). 
Algae experiment Cells/L 
S. marinoi 419,522 
A. longicornis, first experiment 1,285,182 
A. longicornis, second experiment 1,285,182 
 
Seawater for the experiment was filtered with a filtering system consisting of a NVAS UF 
4040 membrane filter, a UV-C light, and a coal filter from Nordisk Vannteknikk AS 
(Drammen, Norway). This filtration system insures that 99.9% of all bacteria and viruses are 
filtered from the sample. The filtered seawater was placed in 3 10 L glass beakers in a cold 
room that held a temperature of about 4°C. The light in the room was set to imitate circadian 
rhythms with 14 hours of daylight and 10 hours of darkness. This was to optimize the 
conditions for algae bloom. A computer controlled the parameters for light and temperature. 
SSRI standards of sertraline, fluoxetine, fluvoxamine, paroxetine and citalopram were added 
to each glass beaker so that the concentration was 1200 ng/L. 
To assure constant mixing of the samples through turbulence, air under pressure was applied 
to the glass beakers through plastic tubing and aquarium rocks in the experiment with S. 
marinoi and in the second experiment with A. longicornis (as illustrated in Figure 9). In the 
first experiment with A. longicornis, air was not applied, as illustrated in Figure 10. 
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Figure 9: Set up of S. marinoi (photo by Kine Smellror). 
 
Figure 10: The first set up of A. longicornis (photo by 
Kine Smellror). 
For each experiment, a control in a 5 L glass beaker containing the same concentration of 
algae as the actual experiment (Table 3) was set up. This was done to look at the over all and 
daily cell growth with the same parameters of light and temperature as the experiment. 
 
To ensure that the growth medium or other experimental parameters did not break down or 
react with the SSRIs, one control for each growth medium, f/2 and Substral, was set up (with 
out algae). These controls were set up in 5 L glass beakers with a concentration of 1200 ng/L 
of the SSRIs as mentioned earlier in this chapter. The glass beakers were manually stirred 
after adding all the ingredients so that the mixture would be homogeneous.  
 
It was decided that a desired concentration for the SSRIs of 300 ng/L for each sample would 
be sufficient because the concentration was in the linear area of the calibration curve. See 
chapter 2.2.6 Calibration Curve for the method development and concentrations of reference 
standards in the calibration curve. 
 
As there were no containers large enough available to hold the amount of seawater needed to 
take out the exact amount of sample (1L*4) for each sampling during the course of the 
experiment with the desired concentration of SSRIs at 300 ng/L, the concentration of SSRIs 
had to be increased to 1200 ng/L so that a volume of 10 L would be more than sufficient to 
take out the samples needed. 1 L of sample was taken from each glass beaker each sampling 
day. The 1 L of sample was then divided into four bottles with 250 mL each and diluted to 1 L 
by adding 750 mL of filtered sea water as described further on in 2.2.3 Centrifuge Set Up. 
This is illustrated under “Extraction” in Figure 8. 
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2.2.2 Chlorophyll a Analysis 
Chlorophyll is the green pigment found in plants and has an important role in their 
photosynthesis as it transforms the energy in photons into sugar. Chlorophyll a (Chl a) is 
found in all algae. Chlorophyll emits fluorescent light and can therefore be measured in a 
fluorometer, the amount of emitted light is directly proportional to the amount of Chl a in the 
cells. Phaeophytin is formed by a degradation of Chl a, with the result in a loss of magnesium 
(Mg) from the porphyrine ring. This compound emits fluorescent light at a different wave 
length than Chl a (58). 
 
Chl a is used in this thesis to give an estimation of the biomass of S. marinoi and A. 
longicornis. A schematic illustration of the Chl a analysis is given in Figure 8. 
 
To determine the amount of Chl a in each glass beaker, samples were taken from them and 
filtered with 25 mm circle GF/C filters from Whatman (GE healthcare, Little Chalfont, United 
Kingdom) in a 12-cylinder filtration device with a vacuum pump, both from EMD Millipore 
Corporation. 
 
The filter papers were put in test tubes and 5 mL of the extractant, ethanol, was then added to 
each test tube. The samples were covered with parafilm to avoid evaporation, and aluminum 
foil to prevent photodegradation, and then set in the refrigerator (4°C) for ca 24 hours. The 
samples were taken out of the refrigerator and added to the cuvettes, and measured when they 
were at room temperature.  
 
To analyze the samples, the fluorometers TD-700 and Trilogy, both from Turner Design 
(Sunnyvale, CA, USA), were used. In the TD-700 fluorometer quarts cuvettes were used, 
while in the Trilogy fluorometer disposable cuvettes of plastic (2.5 mL, 12.5 x 12.5 x 45 mm) 
from Brand GmBH (Wertheim, Germany) were used.  
 
In the TD-700 fluorometer, the Ra-values (the fluorometer reading before acidity) were 
measured first. One drop of 10% HCl was then added to the samples and the Rb-values (the 
fluorometer reading after acidity) were measured. HCl was added to break down the Chl a to 
phaeophytin by removing Mg from the porphyrine ring. The difference in fluorescence 
reading before and after HCl addition is used to infere the amount of active and inactive Chl a 
(59).  
	   22	  
 
The average of the Ra- and Rb-values were used to calculate the amount of Chl a with the 
formula: 
 
µg Chl a L-1 = !  !  (!"!!")
!
     (2.1) 
 
 
Ra and Rb denotes the fluorescence reading before and after HCl, V is volume and F is a 
constant (0.003439) that is adjusted by calibration of the instrument.  
 
Phaeophytin is calculated with the formula: 
 
µg Phaeo L-1 = (!  !   !.!!!"# )!!"
!
    (2.2) 
 
where V is the amount of filtered water in liters (L). 
 





       (2.3) 
 
B0 is the amount of chlorophyll at day one (t0); while B is the amount of chlorophyll at day t. 
µ was used further on to calculate the daily growth of the cells (k) by using the formula: 
 
k = 1.443µ       (2.4) 
 
For the Trilogy fluorometer the Chl a value and the phaeophytin value was calculated directly 
by the instrument, so the average of the Chl a values were used to calculate the overall growth 
of the cells and daily growth of the cells by using formulas 2.3 and 2.4 respectively. 
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2.2.3 Centrifuge Set Up 
This part of the experiment and onwards was conducted at Norut. 
 
Before centrifugation, the samples of 250 mL were diluted to 1 L with 750 mL of filtered 
seawater. 10 mL of a 5M NaOH-solution and 150 ng/L of the internal standards were added, 
as illustrated in Figure 8. 
 
Each 1 L sample was centrifuged at 8000 rounds per minute (RPM) for 10 minutes with either 
a JLA-8.1000 or a JLA-9.1000 rotor in a Beckman Coulter Avanti Centrifuge J-26 XP (Brea, 
CA, USA). The relative centrifugal force (RCF) may be found in Table 4. This was done to 
remove salt that precipitates from the samples when NaOH is added. 
 
Table 4: Shows the radius of the rotors (mm), the maximum rotor speed and the rotor speed used (RPM) and the 
relative centrifugal force (RCF) average and maximum (g = the gravitational force of the rotor). 
 Rotor 
JLA-8.1000 JLA-9.1000 
Rotor radius minimum 119 mm 82 mm 
Rotor radius maximum 222.8 mm 185 mm 
Maximum rotor speed 8000 RPM 9000 RPM 
Rotor speed used 8000 RPM 8000 RPM 
RCF (average) 12250 g 9569 g 
RCF (maximum) 15970 g 13261 g 
 
 
2.2.4 Liquid-Phase Microextraction 
A porous hollow fiber with an inner diameter of 330 µm from Membrana GmBH (Wuppertal, 
Germany) was submerged in dihexylether (DHE) for about 10 seconds. The excess DHE was 
removed using a 3510 ultrasonic bath from Branson Ultrasonics (Danbury, CT, USA) for 
about 3 seconds. The lumen of the hollow fiber was then filled with the acceptor phase, 
MilliQ water adjusted to a pH of about 2 with formic acid. The ends of the hollow fiber were 
then closed with a thin copper thread. The same type of copper thread was then used to hold 
the fiber in the middle of the extraction bottle during the extraction. 
 
The extraction bottles were filled with 1.1 L of the already centrifuged samples. The samples 
were stirred for two hours at 700 RPM with a magnetic stirrer as illustrated in Figure 11 and 
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Figure 12. The liquid inside the lumen of the fibers were transferred to vials for further 




Figure 11: Photo of the LPME set up (photo by Kine 
Smellror). 
 
Figure 12: Photo of the fiber thread during LPME 
(photo by Kine Smellror).  
2.2.5 Ultra Performance Liquid Chromatography and Mass Spectrometry Method Development 
All the SSRIs mentioned in Table 5 were infused into the tandem quadrupole (Xevo TQ-MS 
from Waters Inc.). This was done in order to find the ratio between the mass (m) and the 
charge (z) at which each precursor ion of the SSRIs was detected and at what cone voltage the 
signal for each protonated molecular ion was most intense. To find this signal, a full scan in 
the Tune-page of the MassLynx program from Waters Inc was used. The Tune-page was also 
used to find the product ions. The measured precursor ions were set, one by one, in a product 
ion scan mode. The electron voltage (eV) of the collision energy (Ar as a collision gas) was 
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The observed precursor ions and product ions, the cone voltage and the collision energy are 
summarized in Table 5. 
 
 
Table 5: Monoisotopic mass, observed protonated molecular ion and product ions, cone voltage (CV) and collision 
energy (CE).  
Compound 
Monoisotopic  
        mass 
[M+H]+  
(m/z) 
Product ion 1  
(m/z) 






Citalopram 324.16 325.35 109.05 262.20 35 23 
Citalopram D6 330.20 331.30 109.30 262.40 38 24 
Desmethylcitalopram 310.15 311.30 109.05 262.20 34 20 
Didesmethylcitalopram 296.13 297.30 109.05 262.20 26 21 
Sertraline 305.07 306.25 275.15 
 
18 10 




desmethylsertraline 291.06 292.20 275.15 
 
16 15 
Fluoxetine 309.13 310.35 44.05 
 
22 11 
Fluoxetine D5 314.17 315.25 44.30 
 
22 11 
Norfluoxetine 295.12 296.30 134.15 
 
15 8 
Fluvoxamine 318.16 319.35 71.05 
 
19 13 
Fluvoxamine 318.16 319.35 226.20 
 
19 21 
Paroxetine 329.14 330.30 192.20 
 
37 25 




Detailed parameters for the mass spectrometric method are given in Appendix	  2. 
 
For some of the SSRIs, two product ions were found. This was because there was a high 
intensity for both signals. For quantitative analysis only the product ion with the highest 
intensity was used (“Product ion 1”). The results in Table 5Table 5. 
 
 
Table 5 were used to set up a multiple reaction monitoring (MRM) method used in the 
quantification method. In a MRM method, the first quadrupole will let through the selected 
precursor ion, while the last quadrupole will let through the selected product ion. When the 
ions have passed both quadrupoles an appropriate detector will identify them. This gives 
advantages such as high specificity and high signal-to-noise ratio (S/N). When there is a high 
specificity, one is able to detect the analyte even if there are other substances present in the 
sample. S/N is an important citeria for detection, i.e. the amount of analyte compared to the 
baseline noise. For quantification, a detection limit of S/N=10 is typical (60). 
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2.2.6 Calibration Curve 
For the development of the method and the calibration curve, tap water was used instead of 
filtered seawater. The extraction bottles were filled with 1.1 L tap water, a given amount of 
the different standard SSRIs and internal standards (IS), and 10 mL of 5M NaOH-solution. 
1.1 L tap water was used for the samples since this filled the bottles to a high enough level to 
avoid vortex and bubble formation, which could have lead to the LPME fiber being only 
partly submerged in the sample and giving lower extraction efficiency.  
 
In this experiment the calibration curve compares the area of the peaks of a reference standard 
with that of an internal standard in a ratio plotted against a concentration gradient. The 
calibration curves are then used for quantification of the SSRIs. 
 
The concentrations of the reference standards were 0.91 ng/L, 9.09 ng/L, 45.45 ng/L,     
136.36 ng/L, 272.73ng/L, 545.45 ng/L and 818.18 ng/L. The internal standards were added at 
the same concentration to all samples, 136.36 ng/L. The LPME method was then used, and 
the samples were analyzed by UPLC-MS/MS. 
 
The peaks given in a chromatogram was used to calculate a peak area ratio between the 
reference standards and the internal standards. The peak area ratios were then plotted as a 
function of the concentrations. The regression lines from these plots were then used to 
calculate the concentrations in the experiments. Collecting data for the calibration curve was 
done over four days.  
 
2.2.7 Ultra Performance Liquid Chromatography and Tandem Mass Spectrometry 
The samples were analyzed with ultra performance liquid chromatography tandem mass 
spectrometry (UPLC-MS/MS) with the tandem MS in MRM mode. This was done on an 
Acquity Ultra Performance LC with a Xevo TQ-MS from Waters Corp. (Milford, MA, USA). 
The separation was conducted with a Waters Aquity CSH C18-column (2.1 x 100 mm) with a 
particle size of 1,7 µm, also from Waters Corp. ESI was set to positive mode. Temperature on 
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The optimal elution gradient used in this analysis is shown in Table 6. Both solution A and B 
were made acidic by adding formic acid. The injection volume for these elution gradients was 
5 µL. 
 
Table 6: Optimal elution gradient. Solution A contains MilliQ water with 
0.1% formic acid. Solution B contains acetonitrile with 0.1% formic acid. 




0.00 0.6 80 20 
1.00 0.6 80 20 
8.00 0.6 78.7 21. 3 
 
 
2.2.8 TargetLynx Method 
TargetLynx is a softeare addition to MassLynx and may be used to automatically process 
large amounts of data. In this thesis, to process the results, a TargetLynx method was used.  
This method gave the retention time, height of the curve, area under the curve and the date 
and time for which each sample was run on the UPLC-MS/MS. The AUC for each substance 
from all the samples was compared to the area under the curve for the respective IS.  
 
The use of the deuterated fluoxetine as the IS for fluvoxamine was determined by comparing 
all the IS to fluvoxamine to see which gave the most stable values at a given concentration, 
and looking at the linearity. The linearity (R2) for the fluvoxamine/fluoxetine D5 calibration 
curve was 0.9945. Bergersen et al (61) described a method where they also used fluoxetine 
D5 for the calculations of the fluvoxamine calibration curve with a R2-value of 0.9662. As the 
R2-value for the calibration curve in this experiment was higher, it was decided that the AUC 
for fluvoxamine was to be compared with the IS AUC for fluoxetine. 
 
For parameters for the target lynx method, see Appendix	  3. 
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2.2.9 Software 
For drawing the SSRIs, ChemDraw for iPad version 2.0.1 by PerkinElmer was used. The 
Molecular Mass Calculator by Christoph Golhke was used for the calculation of the 
monoisotopic mass (57). To calculate the RCF for the rotors used, the Beckman Coulter Rotor 
Calculations calculator was used (62).  
 
The UPLC-MS/MS was operated by MassLynx version 4.1 SCN810, copyright © 2010 
Waters Inc. (Milford, MA, USA). TargetLynx version 4.1 SCN810, copyright © 2010 Waters 
Inc. (Milford, MA, USA) was used to collect data from the chromatograms. To analyze the 
data from the TargetLynx software, Microsoct Excel 2011 for Mac was used. 
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3. Results and Discussion 
Pollutants in the environment is an increasing problem, and since 1970 (1) one has been 
aware of pharmaceuticals as pollutants. It has taken some time to establish standard 
environmental risk assessments for pharmaceuticals, and the question of safe disposal and 
removal of pharmaceuticals from sewage treatment plants through sewage sludge and 
biodegradations are being discussed (4, 5).  
 
The environment in the northern parts of Europe has overall lower temperatures and 
differences in daylight with almost no daylight in the winter season, and daylight for up to 24 
hours of daylight during the summer season. This may have an effect on the photochemical 
degradation and the biodegradation of pharmaceuticals, causing them to be more persistent 
than in warmer climates (15). Several studies have proved that SSRIs are found in the 
environment (14, 16-18), and there are also studies that look at the toxicity of the SSRIs (12, 
13, 29). 
 
In this thesis the degradation of SSRIs in monocultures of S. marinoi and A. Longicornis in 
filtered seawater was investigated. Chl a analysis was used to look at the biomass of the 
diatoms. LPME was used for the extraction and up-concentration of the SSRIs, while UPLC-
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3.1 Chlorophyll Analysis 
As there were little or no algae in the ocean outside of Tromsø in the seasonal time when 
conducting this thesis (40), the degradation of SSRIs was looked upon in filtered seawater 
with the presence of the algae S. marinoi and A. longicornis in monocultures. A computer 
controlled the light and temperature parameters, and they were set to optimize algae bloom 
with a daylight length of 14 hours and a temperature of 4°C. If the parameters are favorable 
for a bloom for the diatoms, which may duplicate from 1 cell to 1 million daughter cells in 
less than three weeks (36). 
 
A control containing only filtered seawater and the same concentration of cells as the 
experiments was set up for all the experiments. Chl a were taken the 1st, 7th and 14th day, and 
measured the 2nd, 8th and 15th day for each experiment and for the control. This was to 
measure the biomass. A schematic illustration of this part of the experiment is shown in 
Figure 8 under “Chl a analysis”. The negative values for the growth rate indicate that there are 
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In the S. marinoi experiment, there is a negative overall and daily growth rate for “Beaker 1” 
between the first and the last measurement (Table 7). There is a positive overall and daily 
growth rate between the first and the second measurement, and a negative overall and daily 
growth rate between the second and last measurement. For “Beaker 2” there was a negative 
overall and daily growth rate between the second and the last measurement. For “Beaker 3” 
and the control there was a positive overall and daily growth rate for all the measurements. In 
this experiment the largest daily and overall growth was between the first and the second 
measurements for all the beakers.  
 
Table 7 shows the calculated overall (µ) and daily (k) growth rate for the S. marinoi 
experiment. 
 
Table 7: The calculated overall (µ) and daily (k) growth rate for the S. marinoi experiment. The measurements are 
given in µg/L. For the Ra- and Rb-values used to calculate the overall- and daily growth rate see Appendix	  10. 
Formulas 2.1-2.4 were used for these calculations.  
Growth rate  Measurements  
  First and last 
measurement(µg/L) 
First and second 
measurement(µg/L) 
Second and last 
measurement(µg/L) 
Beaker 1 µ -0,01 0,18 -0,20 
 k -0,01 0,26 -0,29 
     Beaker 2 µ 0,07 0,16 -0,02 
 k 0,10 0,23 -0,03 
     Beaker 3 µ 0,13 0,20 0,07 
 k 0,19 0,29 0,10 
     Control µ 0,26 -0,01 0,53 









	   32	  
In the first experiment with A. longicornis, as shown in Table 8, there was an overall and 
daily positive growth rate for the cells between the first and the last measurement for all the 
beakers and the control. The negative growth between the first and the second measurement 
might be due to A. longicornis algae sticking to the glass walls because of not stirring or 
having air under pressure added to the glass beaker. From day ten manual stirring was started, 
and between the second and the last measurement there was a positive growth rate both 
overall and daily for all the beakers and the control. In this experiment the largest daily and 
overall growth was between the second and the last measurements for all the beakers. 
 
Table 8 shows the calculated overall (µ) and daily (k) growth rate for the first A. longicornis 
experiment. 
 
Table 8: The calculated overall (µ) and daily (k) growth rate for the first A.longicornis experiment. The measurements 
are given in µg/L. For the Ra- and Rb-values used to calculate the overall- and daily growth rate see Appendix	  11. 






First and last 
measurement(µg/L) 
First and second 
measurement(µg/L) 
Second and last 
measurement(µg/L) 
Beaker 1 µ 0,21 -0,08 0,50 
 
k 0,31 -0,11 0,72 
     Beaker 2 µ 0,21 -0,12 0,53 
 
k 0,30 -0,17 0,77 
     Beaker 3 µ 0,20 -0,08 0,49 
 
k 0,29 -0,11 0,70 
     Control µ 0,27 -0,11 0,65 
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In the second A. longicornis experiment there was an overall and daily positive growth rate 
for the cells between all the measurements. For “Beaker 1”, “Beaker 2” and “Beaker 3” the 
largest growth rate was between the second and the last measurement. For the control, the 
largest growth rate was between the first and the second measurement. 
 
The values in Table 9 are calculated from the values given in Appendix	  12 using formulas 
2.1-2.4. 
 
Table 9 shows the calculated overall (µ) and daily (k) growth rate for the second A. 
longicornis experiment. 
 
Table 9: The calculated overall (µ) and daily (k) growth rate for the second A.longicornis experiment.  The 
measurements are given in µg/L. For the Chl a values used to calculate the overall- and daily growth rate see 





First and last 
measurement(µg/L) 
First and second 
measurement(µg/L) 
Second and last 
measurement(µg/L) 
Beaker 1 µ 0.11 0.07 0.15 
 
k 0.16 0.11 0.21 
     Beaker 2 µ 0.12 0.09 0.14 
 
k 0.17 0.13 0.21 
     Beaker 3 µ 0.12 0.09 0.14 
 
k 0.17 0.14 0.20 
     Control µ 0.11 0.12 0.11 
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3.2 Method development 
To optimize the elution gradient, a number of gradients were tried. The mobile phase 
consisted of MilliQ-water with 0.1% formic acid (Solution A) and acetonitrile with 0.1% 
formic acid (Solution B). The first elution gradient was tried because it was used for a similar 
experiment in a master thesis. The three first elution gradients tried are listed in Table 11. 
They were not optimal elution gradients as all the analytes were eluted after less than 2 
minutes, and some analytes co-eluted.  
 
Table 10: Elution gradients tried. 
  The first elution gradient 
The second elution 
gradient 


















0.00 0.6 60 40 80 20 70 30 
1.00 0.6 60 40 80 20 70 30 
7.00 0.6 55 45 70 30 60 40 
12.00 0.6 50 50 60 40 55 45 
 
Another elution gradient that was tried is shown in Table 11. For this elution the analytes did 
not elute within the wanted time set for each sample.  
 
Table 11: Elution gradient tried. 




0.00 0.6 90 10 
1.00 0.6 90 10 
7.00 0.6 85 15 
12.00 0.6 80 20 
 
The elution gradient used in this thesis is listed in Table 6. This is an optimal elution gradient 
since all the analytes eluted between 1 and 8 minutes, the first being didesmethylcitalopram at 
around 1.35 minutes. There was a good enough separation for the purpose of this thesis. This 
is illustrated in the chromatograms that follow in this chapter. 
 
There are more than one analyte in the same time window of elution, which is not optimal, but 
good enough for this thesis. The best solution would be if there were single time windows of 
elution for each analyte. This would increase the sensitivity of the method. 
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3.3 Calibration Curve 
The calibration curve is a quantified expression for the correlation between the known 
concentration of reference standard and the known concentration of an internal standard.  
 
The calibration curve is in this experiment used for quantification of the SSRIs and their 
metabolites by the correlation between concentration of the analytes and the AUC of their 
respective peaks. The lowest concentration on the curve is 0.91 ng/L while the highest 
concentration is 818.18 ng/L. The sampling for the calibration curve was conducted over four 
days, with two parallels each day. 
 
The calibration curve yields a regression line with the formula: 
 
y=mx+b       (2.5) 
 
where m is the slope, and b is the intercept. One wishes the linearity (R2) of the curve to 
approach 1, so that y and x would be proportional, which in turn will give a straight line and 
linearity. As seen in Table 12, the R2-values are approaching 1. Desmethylcitalopram, with 
R2=0.9425, and didesmethylcitalopram, with R2=0.8603, are the lowest R2-values, and are 
therefore less linear than the other SSRIs. There is a weaker correlation between the 
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The formulas for the regression lines given by the calibration curves are applied in the 
calculations of the concentrations and can be seen in Table 12.  
 
Table 12: The SSRIs, their formulas for the regression line and 
the linearity of the regression line (R2) in the calibration curve. 
SSRI y=mx+b R2 
Sertraline y=0.0127x 0.9986 
Desmethylsertraline y=0.0051x 0.9953 
Fluoxetine y=0.0042x 0.9966 
Norfluoxetine y=0.007x 0.9975 
Fluvoxamine y=0.0101x 0.9945 
Paroxetine y=0.0051x 0.9987 
Citalopram y=0.0045x 0.9991 
Desmethylcitalopram y=0.001x 0.9425 
Didesmethylcitalopram y=0.0007x 0.8603 
 
To confirm and remove any outliers in the calibration curves a q-test was used. The formula 




       (2.6) 
 
Gap is the absolute difference between the value one wants to test as an outlier and the value 
closest to it, while range is the absolute difference between the minimum and maximum 
values in the dataset. The q-value calculated is then compared to a given value, Q, in a table 
corresponding to the sample size and the confidence level. If q > Q, then the value in question 
is rejected. 
 
There are many metabolites for the different SSRIs, but the only standards available for this 
study were desmethylsertraline, norfluoxetine, desmethylcitalopram and 
didesmethylcitalopram. This in turn implies that other metabolites for the SSRIs would not be 
detected through the method used. 
 
Since, in this thesis, one did not work with low concentrations, limit of detection and limit of 
quantification was not tested. Some of the average measured concentrations were below the 
lowest concentration of the standard curve, but this is not of importance since it was the 
decrease in concentration over time that was of interest. 
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Examples of chromatograms of the calibration curve for the concentration 272.73 ng/L for all 
the precursor ions of the SSRIs and their fragment ions detected with an MRM-method are 
shown in Figure 13 and Figure 14.  
 
Figure 13: Chromatogram of the calibration curve (272.73 ng/L) for all the ions for rac-trans-paroxetine D4, 
paroxetine, citalopram D6, citalopram and fluvoxamine. 
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Figure 14: Chromatogram of the calibration curve (272. ng/L) for all the ions for desmethylcitalopram, fluoxetine D5, 
fluoxetine, sertraline D3, sertraline, didesmetylciralopram, norfluoxetine and desmethylsertraline. 
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3.4 Extraction of Blank Samples 
Examples of chromatograms of a blank sample (containing just MilliQ-water) for all the 
precursor ions of the SSRIs and the fragment ions used in the TargetLynx-method detected 
with an MRM-method are shown in Figure 15 and Figure 16. 
 
Figure 15: Chromatogram of a blank sample for rac-trans-paroxetine D4, paroxetine, citalopram D6, citalopram, 
fluvoxamine and desmethylcitalopram. 
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Figure 16: Chromatogram of a blank sample for fluoxetine D5, fluoxetine, sertraline D3, sertraline, 
didesmetylciralopram, norfluoxetine and desmethylsertraline. 
Some blank samples that were extracted had “carry-over” effects with analytes like 
citalopram and sertraline, i.e. that the analyte was eluted with the blank samples. This 
happened following a sample with a high concentration. The AUC of for example citalopram 
in the blank sample would be about 1/1000 of the AUC in the actual samples. This has no 
significance for the calculations of the average measured concentrations. 
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3.5 Control Experiment Without Diatoms 
To ensure that the growth medium  (f/2 and Substral) or the other parameters in the 
experiment (light conditions and temperature) did not influence the measured SSRI 
concentrations, a control experiment was set up.  The set up for both the controls were 
identical to the set ups for the experiments with the algae, except for not applying air under 
pressure. This was because constant mixing of the samples did not seem necessary as the 
SSRIs and the growth medium would be homogenous after manually stirring them once. 
 
Exact values for average concentrations, standard deviations, and relative standard deviations 
(RSD) for each SSRI are found in Appendix	  6. For each sampling, three parallels were run. 
An overview is given in Figure 15 to Figure 23.  
 
There were no measurements taken on the first day. The decrease or increase in average 
measured concentration between day 6 and day 14 is therefore used to calculate the average 
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There is a decrease in the average measured concentrations for both growth mediums for all 
the SSRIs. For sertraline (Figure 17) the decrease in average measured concentration for the 
f/2 growth medium was 8% from day 6 to day 14, with an average decrease per day of 1.00%. 
The decrease for Substral during the same period was 3%, with an average decrease of 0.38% 
per day. 
 
For fluoxetine (Figure 18), the f/2 growth medium the average measured concentration from 
day 6 to day 14 decreased with 11%, and for the Substral growth medium there was a 
decrease of 9% from day 6 to day 14. The average decrease per day was 1.38% for the f/2 
medium and 1.13% for Substral. 
 
Figure 17: The average measured concentrations for 
sertraline for each growth medium for each sampling 
day. The standard deviation for each growth medium is 
also shown. 
 
Figure 18: The average measured concentrations for 
fluoxetine for each growth medium for each sampling 
day. The standard deviation for each growth medium is 
also shown. 
For fluvoxamine (Figure 19) the decrease in the average measured concentration of the f/2 
medium for day 6 to day 14 was 9%, which corresponds to a daily decrease of 1.13%. For the 
Substral medium the decrease in average measured concentration for day 6 to day 14 was 6%, 
with a daily decrease of 0.75%. 
 
Figure 19: The average measured concentrations for 
fluvoxamine for each growth medium for each sampling 
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Paroxetine (Figure 20) had the highest decrease in the average measured concentration of the 
Substral medium from day 6 to day 14 (24%). This gives a daily decrease of 3.00%. The 
decrease in f/2 medium for the average measured concentration in the same period was 13%, 
which corresponds to a daily decrease of 1.63%.  
 
Citalopram (Figure 21) had a lower decrease with 6% for the average measured concentration 
for the f/2 growth medium, and 3% for the Substral growth medium from day 6 to day 14. 




Figure 20: The average measured concentrations for 
paroxetine for each growth medium for each sampling 
day. The standard deviation for each growth medium is 
also shown. 
 
Figure 21: The average measured concentrations for 
citalopram for each growth medium for each sampling 
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The average measured concentrations for desmethylsertraline (Figure 22), norfluoxetine 
(Figure 23) and didesmethylcitalopram (Figure 24) are below the lowest concentration in the 
calibration curve, hence the average measured concentrations are uncertain compared to those 
that are within the calibration curve.  
 
Desmethylsertraline had an increase in the average measured concentration for the f/2 growth 
medium of 21% and 21% for the Substral medium. This gives a daily increase of 9.63% for 
f/2 and 2.63% for Substral. 
 
For norfluoxetine the increase in the average measured concentrations from day 6 to day 14 
was 23% for the f/2 medium and 61% for the Substral growth medium, which correspond to a 




Figure 22: The average measured concentrations for 
desmethylsertraline for each growth medium for each 
sampling day. The standard deviation for each growth 
medium is also shown. 
 
Figure 23: The average measured concentrations for 
norfluoxetine for each growth medium for each sampling 






























Day	  14	   0	  
0,5	  
1	  















	   45	  
Didesmethylcitalopram had a decrease in the average measured concentration from day 6 to 
day 14 of 65% for the f/2 growth medium. This gives a daily decrease of 8.13%. For the 
Substral growth medium there was a 55% decrease from day 6 to day 14, with a daily 
decrease of 6.88%. 
 
Desmethylcitalopram (Figure 25) is the only one of the metabolites analyzed that has average 
measured concentrations above the lowest concentration on the standard curve. For the f/2 
growth medium the decrease in the average measured concentration for day 6 to day 14 was 
1.6%, and for the Substral growth medium an increase in 2%. This gives a daily increase of 
0.20% for the f/2 medium and a no significant daily increase for Substral (0.25%).  
 
 
Figure 24: The average measured concentrations for 
didesmethylcitalopram for each growth medium for each 
sampling day. The standard deviation for each growth 
medium is also shown. 
 
Figure 25: The average measured concentrations for 
desmethylcitalopram for each growth medium for each 
sampling day. The standard deviation for each growth 
medium is also shown. 
 
In the control experiment that contained the growth mediums and the SSRIs there seems to be 
little lowering of the average measured concentrations for sertraline, fluoxetine, fluvoxamine, 
citalopram. The slight decrease in concentration might indicate that the growth mediums, light 
settings, temperature and filtered seawater do not have a big impact on these SSRIs in general. 
The decrease in sertraline and fluoxetine indicates that a small amount of sertraline and 
fluoxetine is degraded to desmethylsertraline and norfluoxetine respectably. This may indicate 
that sertraline and fluoxetine is degraded by light or other parameters. Paroxetine had a 
decrease of 24% for the average measured concentration of Substral, which might indicate 
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There were different average measured concentrations for the two growth mediums for all the 
samples taken. In theory, the average measured concentrations should be the same as the 
concentrations of the SSRIs added to the glass beakers. Substral had a constant lower average 
measured concentration, except for paroxetine. The lower measurements in Substral indicate 
the presence of some compounds with a slight effect on the extraction efficiency or the 
stability of the SSRIs in the samples.  
 
Examples of chromatograms of the control experiment for all the SSRI ions used in the 
quantification method are shown in Figure 26 and Figure 27. Examples of chromatograms of 
the Substral growth medium may be found in Appendix 5. 
 
In Figure 27, one can clearly see that there is a lower signal for didesmethylcitalopram than 
for the other analytes, and the S/N ratio is lower than 10, which means that it is below the 
quantification limit and the measured concentration is highly uncertain. For 
desmethylsertraline and norfluoxetine, the signal is 103 lower than for the other analytes. 
These low signals reflect their average measured concentration. 
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Figure 26: Chromatogram of the f2 growth medium for rac-trans-paroxetine D4, paroxetine, citalopram D6, 
citalopram, fluvoxamine and desmethylcitalopram. 
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Figure 27: Chromatogram of the f2 growth medium for fluoxetine D5, fluoxetine, sertraline D3, sertraline, 
didesmetylciralopram, norfluoxetine and desmethylsertraline. The red circle indicates the peak for 
didesmethylcitalopram. 
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3.6 Concentrations of Selective Serotonin Reuptake Inhibitors 
Three experiments were conducted in total for this thesis. The two diatoms S. marinoi and A. 
longicornis were used in the experiments in monocultures. The first experiment included S. 
marinoi, while the two others included A. longicornis. For each experiment 3 10L glass 
beakers were set up. Figure 8 illustrates one of these 3 glass beakers and the tests conducted 
(“Chl a analysis” and “Extraction”). For each of the sampling days, three parallels were run 
for the “Extraction”-part of the experiment for each “beaker”.  
 
In the graphs “Parallel 1” refers to beaker number 1, “Parallel 2” is beaker number 2 and 
“Parallel 3” is beaker number 3. In the graphs each column is the average measured 
concentration for the three parallels from each experiment as shown in Figure 8. 
 
3.6.1 Concentrations of Selective Serotonin Reuptake Inhibitors in the S. marinoi Experiment 
The experiment with S. marinoi was the first experiment conducted. S. marinoi forming 
agglomerates at the bottom of the glass beakers was observed from day 2, even though there 
was added air under pressure to create turbulence .  
 
Detailed measured average concentrations, SD and RSD % for this experiment are found in 
Appendix	  7, while an overview is given in Figure 28 to Figure 36.  
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For sertraline (Figure 28) there was a decrease in the average measured concentration of 39% 
from day 1 to day 7 for the parallels combined. From day 7 to day 14 there was a decrease of 
27%, while the overall decrease from day 1 to 14 was 55% in the average measured 
concentration. The daily decrease from day 1 to day 14 was 3.93%. 
 
Figure 28: The average measured concentrations of sertraline for each parallel 
experiment for each sampling day in the S. marinoi experiment. The standard 
deviation for each parallel experiment is also shown. 
Fluoxetine (Figure 29) has a decrease in the average measured concentration of 95% from day 
1 to day 7 for the parallels combined, and a decrease of 48% from day 7 to day 14. The 
majority of the decrease happened in the duration of the first 7 days, making the decrease in 
the last 7 days irrelevant. The overall total decrease from day 1 to day 14 was 98%, with a 
daily decrease of 7%. From day 1 to day 3 there was 70% decrease. This gives a daily 
decrease of 23.33% for the first 3 days.  
 
Figure 29: The average measured concentrations of fluoxetine for each parallel 
experiment for each sampling day in the S. marinoi experiment. The standard 
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Fluvoxamine (Figure 30) had the fastest decline in average measured concentration of all the 
SSRIs in this experiment. The decrease in average measured concentration for all the parallels 
was 99.5% from day 1 to day 7. From day 7 to day 14 the decrease was 20%, this decrease is 
irrelevant as the majority of the decrease happened in the first 7 days. The overall decrease 
from day 1 to day 14 was 99.6%. This shows that fluvoxamine is completely broken down 
already after 7 days, more so than fluoxetine. The daily decrease in the average measured 
concentration was 7.11%. From day 1 to day 3 there was 81% decrease. This gives a daily 
decrease of 27.00% for the first 3 days. 
 
Figure 30: The average measured concentrations of fluvoxamine for each parallel 
experiment for each sampling day in the S. marinoi experiment. The standard 
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For paroxetine (Figure 31) the decrease in the average measured concentration from day 1 to 
day 7 for all the parallels combined was 48%, the same decrease was measured from day 7 to 
day 14. The overall decrease in the average measured concentration from all the parallels 
combined from day 1 to day 14 was 73%, which corresponds to a daily decrease of 5.21%.  
 
Figure 31: The average measured concentrations of paroxetine for each 
parallel experiment for each sampling day in the S. marinoi experiment. The 
standard deviation for each parallel experiment is also shown. 
 
Citalopram (Figure 32) had the lowest decrease in the average measured concentration of all 
the SSRIs in this experiment. For all the parallels combined, there was a decrease in 6% from 
day 1 to day 7.  From day 7 to day 14 the decrease was only 2%, while the overall decrease 
from day 1 to day 14 was 8%. The daily decrease from day 1 to day 14 was 0.57%. 
 
Figure 32: The average measured concentrations of citalopram for each 
parallel experiment for each sampling day in the S. marinoi experiment. The 














































	   53	  
Desmethylsertraline (Figure 33), norfluoxetine (Figure 34), and didesmethylcitalopram 
(Figure 35) have average measured concentrations below the lowest concentration in the 
calibration curve, so the average measured concentrations are uncertain compared to those 
that are within the calibration curve.  
 
For desmethylsertraline there is an increase in the average measured concentration from day 1 
to day 7 of 181%, and 58.72% from day 7 to day 14. The increase in the average measured 
concentration from day 1 to day 14 is 347%. This gives a daily increase of 19.28%. There is a 
weak trend in the increasing concentration of desmethylsertraline that indicates that sertraline 
is degraded to desmethylsertraline, but the concentrations measured of desmethylsertraline are 
nowhere near of being equivalent to what is degraded from the sertraline concentration. This 
might indicate that other metabolites are formed or that sertraline accumulate in the diatoms. 
 
Figure 33: The average measured concentrations of desmethylsertraline for each 
parallel experiment for each sampling day in the S. marinoi experiment. The 
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For norfluoxetine there is an increase from day 1 to day 3, but a decrease in the average 
measured concentration from day 1 to day 7 of 9% and from day 7 to day 14 of 25.57%. 
The overall decrease in the average measured concentration was 25.57% from day 1 to day 
14. This gives a daily decrease of 1.83%. The concentrations are lower than what would be 
expected given the degradation of fluoxetine, indicating that norfluoxetine show no trend of 
being formed during the experiments. 
 
Figure 34: The average measured concentrations of norfluoxetine for each parallel 
experiment for each sampling day in the S. marinoi experiment. The standard 
deviation for each parallel experiment is also shown. 
 
Didesmethylcitalopram has an increase in average measured concentration of 380% the first 7 
days, and a decrease of 72% from day 7 to day 14. There is an overall increase from day 1 to 
day 14 of 35%. The low concentrations of didesmethylcitalopram indicate that there is no 
trend of it being formed during the experiment. 
 
Figure 35: The average measured concentrations of didesmethylcitalopram for 
each parallel experiment for each sampling day in the S. marinoi experiment. 
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Desmethylcitalopram (Figure 36) is the only one of the metabolites analyzed that has average 
measured concentrations above the lowest concentration on the standard curve. 
Desmethylcitalopram had an increase in the average measured concentration for all the 
parallels combined of 178% from day 1 to day 7. From day 7 to day 14 the increase was 
133%, while the overall increase from day 1 to day 14 was 546%. This gives a daily increase 
of 39.00%. The average measured concentrations for desmethylcitalopram are low, but 
degradation from citalopram to desmethylcitalopram is indicated. This trend is not visible for 
didesmethylcitalopram. 
 
Figure 36: The average measured concentrations of desmethylcitalopram for 
each parallel experiment for each sampling day in the S. marinoi experimen. 
The standard deviation for each parallel experiment is also shown. 
 
Examples of chromatograms of the S. marinoi experiment for all the SSRI ions used in the 
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Figure 37: Chromatogram of the S. marinoi experiment for rac-trans-paroxetine D4, paroxetine, citalopram D6, 
citalopram, fluvoxamine and desmethylcitalopram for day 3 of the experiment. 
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Figure 38: Chromatogram of the S. marinoi experiment for fluoxetine D5, fluoxetine, sertraline D3, sertraline, 
didesmetylciralopram, norfluoxetine and desmethylsertraline for day 3 of the experiment. The red circle indicates the 
peak for didesmethylcitalopram.   
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3.6.2 Concentrations of Selective Serotonin Reuptake Inhibitors in the First A. longicornis 
Experiment 
In this experiment there was no added air under pressure to the three glass beakers. The         
A. longicornis, drifted down and sedimented at the bottom of the beakers. This was not 
discovered until day 8 in the experiment because of the monitoring of cell growth, and from 
that day of the experiment all three beakers were manually stirred every day except for day 11 
and 12. This has most likely had an impact on the average measured concentrations, and will 
be discussed later. 
 
Detailed measured average concentrations, SD and RSD % for this experiment are found in 
Appendix	  8, while an overview is given in Figure 39 to Figure 47. 
 
Sertraline, fluoxetine, paroxetine and citalopram had an increase in concentration during the 
first days of the experiment. An increase in concentration should not occur, and the cause for 
this increase might be that there is something with these samples that make the extraction of 
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Sertraline (Figure 39) had an increase in the average measured concentration for all the 
parallels combined of 11% from day 1 to day 7. There was a decrease of 26% in average 
measured concentration for all the parallels combined from day 7 to day 14, and an overall 
decrease from day 1 to day 14 of 18%. This gives a daily decrease of 1.29%. An increase in 
the concentration is not possible and is probably due to the extraction or quantification 
method. It is most likely that the decrease in average measured concentration did not occur 
until manual stirring of the glass beakers was initiated. 
 
Figure 39: The average measured concentrations of sertraline for each parallel 
experiment for each sampling day in the first A. longicornis experiment. The 
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Fluoxetine (Figure 40) had an increase in the average measured concentration of 6% from day 
1 to day 2 for all the parallels combined. From day 1 to day 7, however, there was a decrease 
of 0.8%. From day 7 to day 14 there was a decrease of 9%. There was a total decrease in the 
average measured concentration of 10% from day 1 to day 14 for all the parallels combined, 




Figure 40: The average measured concentrations of fluoxetine for each parallel 
experiment for each sampling day in the first A. longicornis experiment. The 
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Fluvoxamine (Figure 41) had an increase in average measured concentration from day 1 to 
day 7 of 3% for all the parallels combined. From day 7 to day 14 there was a decrease in the 
average measured concentration of 5%, with an overall decrease from day 1 to day 14 of 3% 
for all the parallels combined. There was a daily decrease of 0.21% from day 1 to day 14. Just 
as for sertraline, an increase in the concentration is not possible and is probably due to the 
extraction or quantification method. It is also most likely that the decrease in average 
measured concentration did not occur until manual stirring of the glass beakers was initiated.  
 
Figure 41: The average measured concentrations of fluvoxamine for each parallel 
experiment for each sampling day in the first A. longicornis experiment. The 
standard deviation for each parallel experiment is also shown. 
 
Paroxetine (Figure 42) had a decrease of 7% from day 1 to day 7 in the average measured 
concentration for all the parallels combined. From day 7 to day 14 the decrease was 21%, and 
from day 1 to day 14 the decrease was 27%, which corresponds to a daily decrease of 1.93%. 
 
Figure 42: The average measured concentrations of paroxetine for each parallel 
experiment for each sampling day in the first A. longicornis experiment. The 
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Citalopram (Figure 43) had an increase of 7% from day 1 to day 7 in the averaged measured 
concentration for all parallels combined. The increase from day 7 to day 14 was 3%, while the 
overall increase from day 1 to day 14 was 10%. This gives a daily increase of 0.71%. Just as 
with sertraline and fluvoxamine, it is most likely that the decrease in average measured 
concentration did not occur until manual stirring of the glass beakers was initiated. Just as for 
sertraline and fluyvoxamine, an increase in the concentration is not possible and is probably 
due to the extraction or quantification method. It is also most likely that the decrease in 





Figure 43: The average measured concentrations of citalopram for each parallel 
experiment for each sampling day in the first A. longicornis experiment. The standard 
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Desmethylsertraline (Figure 44) and didesmethylcitalopram (Figure 45) had average 
measured concentrations below the lowest concentration in the calibration curve, so the 
average measured concentrations are uncertain compared to those that are within the 
calibration curve. The low concentrations of these metabolites are reflected in the 
chromatogram in Figure 49. 
 
For desmethylsertraline there was an increase in the average measured concentration from day 
1 to day 7 of 207%, and from day 7 to day 14 of 34%. The overall increase from day 1 to day 
14 was 310%, giving a daily increase of 22.14%. Even though the concentrations are low, 




Figure 44: The average measured concentrations of desmethylsertraline for each 
parallel experiment for each sampling day in the first A. longicornis experiment. The 
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Didesmethylcitalopram had an increase in the average measured concentration from day 1 to 
day 7 of 140%. From day 7 to day 14 there was a decrease of 12%, and an overall increase in 
the average measured concentration from day 1 to day 14 of 112%. This gives a daily increase 
of 8.00%. There is a considerable variation in the measurements for didesmethylcitalopram, 




Figure 45: The average measured concentrations of didesmethylcitalopram for each 
parallel experiment for each sampling day in the first A. longicornis experiment. The 
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The first three measurements for norfluoxetine (Figure 46) and desmethylcitalopram (Figure 
47) are below the lowest concentration of the calibration curve. For norfluoxetine, the 
increase in average measured concentrations for all parallels was184% from day 1 to day 7, 
and 79% between day 7 and 14. The overall increase in average measured concentration was 
410% from day 1 to day 14, giving a daily increase of 29.29%. The concentrations are low, 





Figure 46: The average measured concentrations of norfluoxetine for each parallel 
experiment for each sampling day in the first A. longicornis experiment. The 
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Desmethylcitalopram had an increase in the average measured concentration of 151% from 
day 1 to day 7. There was a decrease in the average measured concentration of 11% from day 
7 to day 14. From day 1 to day 14 the increase was 124%, which corresponds with a daily 
increase of 8.86%. The average measured concentrations for desmethylcitalopram are low, 




Figure 47: The average measured concentrations of desmethylcitalopram for each 
parallel experiment for each sampling day in the first A. longicornis experiment. The 
standard deviation for each parallel experiment is also shown. 
 
Examples of chromatograms of the first A. longicornis experiment for all the SSRI ions in the 
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Figure 48: Chromatogram of the first A. longicornis experiment for rac-trans-paroxetine D4, paroxetine, citalopram 
D6, citalopram, fluvoxamine and desmethylcitalopram for day 3 of the experiment. 
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Figure 49: Chromatogram of the first A. longicornis experiment for fluoxetine D5, fluoxetine, sertraline D3, sertraline, 
didesmetylciralopram, norfluoxetine and desmethylsertraline for day 3 of the experiment. The red circle indicates the 
peak for didesmethylcitalopram.  
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3.6.3 Concentrations of Selective Serotonin Reuptake Inhibitors in the Second A. longicornis 
Experiment 
Since it was discovered that stirring in the samples might have an impact on the results in the 
first A. longicornis experiment, air under pressure was added to all three glass beakers, giving 
turbulence so that the A. longicornis would be suspended in the sample. To begin with, there 
was manually stirring as well, except for days 5 and 6, until day 9. At day 10 there was 
discovered a bacterial contamination in “Parallel 3”, and at day 11 in “Parallel 2”. At day 14 
the bacterial contamination was present in “Parallel 1” as well. This is illustrated in Figure 50. 




Figure 50: Set up of the second A. longicornis experiment. ”Parallel 2” and ”Parallel 3” are opalescent, which 
indicates a bacterial contamination. (Picture taken by: Kine Smellror) 
 
Detailed measured average concentrations, SD and RSD % for this experiment are found in 
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For sertraline (Figure 51) there was a decrease in the average measured concentration of 67% 
for all parallels combined from day 1 to 9. From day 9 to day 16 the decrease was 32%, while 
the overall decrease from day 1 to day 16 was 78%, which corresponds to a daily decrease of 
4.88%. From day 2, “Parallel 2” had a higher average measured concentration than the two 




Figure 51: The average measured concentrations of sertraline for each parallel 
experiment for each sampling day in the second A. longicornis experiment. The 
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Fluoxetine (Figure 52) has an increase in the average measured concentration from day 1 to 
day 2 of 31% for all the parallels combined. This increase in concentration should not occur, 
and as mentioned before, this might be because of the efficiency of the extraction or the 
quantification method. From day 2 to day 9 there was a decrease of 68%. A 58% decrease was 
observed from day 1 to day 9, and from day 9 to day 16 there is a decrease of 48% for the 
average measured concentration for all parallels combined. The overall decrease from day 1 
to day 16 was 78%. This gives a daily decrease of 4.88%. From day 3, “Parallel 3” shows a 
higher concentration than the other two parallels. “Parallel 1” and “Parallel 2” combined show 





Figure 52: The average measured concentrations of fluoxetine for each parallel 
experiment for each sampling day in the second A. longicornis experiment. The 
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For fluvoxamine (Figure 53), when combining all the parallels, there is a decrease in the 
average measured concentration of 87% from day 1 to day 9, 43% from day 9 to day 16, and 
93% from day 1 to day 16, giving a daily decrease of 5.81%. “Parallel 3” shows a higher 
concentration from day 3, just as in fluoxetine. “Parallel 1” and “Parallel 2” combined show a 
decrease of 99% from day 1 to day 16, while “Parallel 3” only had a 80% decrease in that 
same period.  
 
Figure 53: The average measured concentrations of fluvoxamine for each parallel 
experiment for each sampling day in the second A. longicornis experiment. The 
standard deviation for each parallel experiment is also shown. 
 
For paroxetine (Figure 54) there was a decrease in the average measured concentration for all 
the parallels combined of 44% from day 1 to day 9 and 42% from day 9 to day 16. The overall 
decrease in the average measured concentration from day 1 to day 16 was 47%. This gives a 
daily decrease of 2.94%. “Parallel 3” has a higher average measured concentration from day 
3. 
 
Figure 54: The average measured concentrations of paroxetine for each parallel 
experiment for each sampling day in the second A. longicornis experiment. The 
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Citalopram (Figure 55) has an increase in the average measured concentration of 33% for all 
the parallels combined from day 1 to day 2. There cannot be an actual increase in 
concentration, but rather indicating an uncertainty in the extraction or quantification method. 
It is more likely to be the quantification method. The values from day 2 to day 16 give a more 
realistic view, and will be used from this point onwards. From day 2 to day 9 there is an 
increase in the average measured concentration of 1%, but from day 9 to day 16 there is a 
decrease of 5%. From day 2 to day 16 there is a decrease in the average measured 




Figure 55: The average measured concentrations of citalopram for each parallel 
experiment for each sampling day in the second A. longicornis experiment. The 
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Desmethylsertraline (Figure 56) and didesmethylcitalopram (Figure 57) had average 
measured concentrations below the lowest concentration in the calibration curve, so the 
average measured concentrations are uncertain compared to those that are within the 
calibration curve. Desmethylsertraline had an increase in the average measured concentration 
from day 1 to day 9 of 6%. From day 9 to day 16 the increase was 22%, and the overall 
increase from day 1 to day 16 was 19%, giving a daily increase of 1.19%. Desmethylsertraline 
have a higher concentration of “Parallel 2”, just like sertraline. The average measured 




Figure 56: The average measured concentrations of desmethylsertraline for each 
parallel experiment for each sampling day in the second A. longicornis experiment. 
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For didesmethylcitalopram there is an increase in the average measured concentration from 
day 1 to day 9 of 71%, while from day 9 to day 16 there is a decrease of 35%. This gives an 
overall increase in the average measured concentration of 10% from day 1 to day 16, with a 
daily increase of 0.63%. There is a considerable variation in the measurements for 




Figure 57: The average measured concentrations of didesmethylcitalopram for each 
parallel experiment for each sampling day in the second A. longicornis experiment. 
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For norfluoxetine (Figure 58) the average measured concentrations are above the lowest 
concentration for the calibration curve from day 2 for “Parallel 2” and “Parallel 3”, and 
“Parallel 1” from day 3. The average measured concentration for “Parallel 1” increases with 
191% from day 1 to day 3, and decreases with 80% from day 3 to day 16. The other two 
parallels increase with 287% from day 1 to day 9, and decrease with 15% from day 9 to day 
16. There is an overall increase in the average measured concentration of 228% from day 1 to 
day 16, which corresponds to a daily increase of 14.25%. This increase in the average 
measured concentration, even though the concentrations are low, indicates that fluoxetine 




Figure 58: The average measured concentrations of norfluoxetine for each parallel 
experiment for each sampling day in the second A. longicornis experiment. The 
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For desmethylcitalopram (Figure 59) the average measured concentrations are above the 
lowest concentration for the calibration curve from day 2. From day 1 to day 9 there was an 
increase of 480%, while from day 2 to day 9 there was an increase of 231% for all parallels 
combined. From day 9 to day 16 there was a low increase of 14%, and the overall increase 
from day 1 to day 16 was 561%. This gives a daily increase of 35.06%. Citalopram has a 
measured (not real) increase in concentration from day 1 to day 9, especially from day 1 to 
day 2. There is a decrease in the citalopram average measured concentration from day 9 to 




Figure 59: The average measured concentrations of desmethylcitalopram for each 
parallel experiment for each sampling day in the second A. longicornis experiment. 
The standard deviation for each parallel experiment is also shown. 
 
 
Fluoxetine, fluvoxamine and paroxetine had a higher average measured concentration in 
“Parallel 3” than in the other parallels. There was observed less air under pressure in “Parallel 
3”. This could have had an effect on the average measured concentration, especially since 
manual stirring stopped after day 9 due to bacterial contamination. The bacterial 
contamination might also have affected the average measured concentration. The bacterial 
contamination was observed in “Parallel 3” first. This may have affected the average 
measured concentrations for fluoxetine, fluvoxamine and paroxetine as well. 
 
Examples of chromatograms of the second A. longicornis experiment for all the SSRI ions in 
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Figure 60: Chromatogram of the second A. longicornis experiment for rac-trans-paroxetine D4, paroxetine, 
citalopram D6, citalopram, fluvoxamine and desmethylcitalopram for day 3 of the experiment. 
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Figure 61: Chromatogram of the second A. longicornis experiment for fluoxetine D5, fluoxetine, sertraline D3, 
sertraline, didesmetylciralopram, norfluoxetine and desmethylsertraline for day 3 of the experiment. The red circle 
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3.7 Comparing the Experiments 
In the S. marinoi experiment the largest daily and overall growth rate was between the first 
and second measurements, i.e. between day 1 and day 7. The largest decrease in the average 
measured concentrations for fluoxetine and fluvoxamine was between day 1 and day 7 in the 
experiment, while the other SSRIs, sertraline, paroxetine and citalopram, had a larger 
decrease from day 7 to day 14.  
 
In the first A. longicornis experiment the largest daily and overall growth rate was between 
day 7 and day 14. Sertraline, fluoxetine, fluvoxamine and paroxetine had the largest decreases 
in the average measured concentrations in this period compared to the first 7 days. This might 
have been caused by the lack of stirring and turbulence from added air under pressure the first 
8 days.  
 
The second A. longicornis experiment also had the largest daily and overall growth rate was 
between day 7 and day 14. This was to be expected. The decreases in the average measured 
concentrations from day 1 to day 9 were largest for sertraline, fluoxetine, fluvoxamine and 
paroxetine. 
 
There is an overall constant decrease of the average measured concentration of the SSRIs, but 
over time it seems that the concentrations do not have an effect on the algae growth. 
 
The first A. longicornis experiment has a lower decrease and increase in average measured 
concentrations than the second A. longicornis experiment. This is probably due to the lack of 
turbulence in the glass beakers because air under pressure was not applied. This was not 
discovered until day 8 of the experiment. The S. marioni experiment will therefor be 
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Table 13 shows the decrease of average measured concentrations of all the experiments in % 
between the first and the last day of the experiments. The S.marinoi experiment and the A. 
longicornis experiment were conducted over 14 days, while the second A.longicornis 
experiment was conducted over 16 days. This might have had an effect on the decrease and 
increase in average measured concentrations. 
 
The S. marinoi experiment had a large decrease in average measured concentrations for 
fluoxetine, fluvoxamine, paroxetine and citalopram compared to the decrease in average 
measured concentrations of A. longicornis, while A. longicornis had a larger decrease than    
S. marinoi in average measured concentration for sertraline. 
 
Table 13: The decrease of the average measured concentration in % for each SSRI from the first to the last day of 
each experiment. A. Longicornis 1 refers to the first A. Longicornis experiment, while A. Longicornis 2 refers to the 
second A. Longicornis experiment. 
 Experiment 
SSRI S. marinoi A. longicornis 1 A. longicornis 2 
Sertraline 55%  18%  78%  
Fluoxetine 98% (95%)* 10%  78%  
Fluvoxamine 99.6% (99.5%)* 4% 93% (87%)* 
Paroxetine 73%  27% 47%  
Citalopram 8% 0  4% 
*Degradation from day 1 to day 7 given in parenthesis.   
 
From Table 13 one sees that in the S. marinoi experiment fluoxetine and fluvoxamine had a 
higher decrease in the average measured concentrations compared the other SSRIs. Fluoxetine 
and fluvoxamine had a decrease of 98% and 99.6% respectably from day 1 to day 14, but 
already after 7 days fluoxetine had decreased with 95% and fluvoxamine had decreased with 
99.5%. In the second A. longicornis experiment fluvoxamine had the highest decrease in the 
average measured concentration compared to the other SSRIs with a 93% decrease from day 1 
to day 14, and a decrease of 87% the first 7 days. Fluoxetine had a decrease of 78% from day 
1 to day 14. This shows that fluoxetine and fluvoxamine were the least stable SSRIs. 
 
Citalopram had a stable average measured concentration in both experiments, with low 
degradation, and sertraline had a decrease of 55% in the S. marinoi experiment and 78% in 
the second A. longicornis experiment. 
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Table 14 shows the daily decrease of average measured concentrations of all the experiments 
in % between the first and the last day of the experiments.  
 
Table 14: The decrease of the daily average measured concentration in % for each SSRI from the first to the last day 
of each experiment. A. Longicornis 1 refers to the first A. Longicornis experiment, while A. Longicornis 2 refers to the 
second A. Longicornis experiment. 
 Control Experiment 




Sertraline 1.00% 0.38% 3.93%  1.29%  4.88%  
Fluoxetine 1.38% 1.13%  7.00% (13.57%)* 0.71%  4.88%  
Fluvoxamine 1.13%  0.75%  7.11% (14.21%)*  0.21%  5.81% (9.67%)* 
Paroxetine 1.63%  3.00%  5.21%  1.93%  2.94%  
Citalopram 0.75%  0.38%  0.57%  0 0.27% 
* Degradation from day 1 to day 7 given in parenthesis.   
 
For the average measured concentrations in the S. marinoi experiment, both fluoxetine 
(7.00%) and fluvoxamine (7.11%) have a higher daily decrease in concentration than the other 
SSRIs from day 1 to day 14. Fluvoxamine had a daily decrease of 13.57% the first seven 
days, while fluoxetine hade a daily decrease of 14.21% in the same period. In the second A. 
longicornis experiment, there was a high daily decrease of fluvoxamine (5.81%) compared to 
the other SSRIs from day 1 to day 16, with daily decrease of 9.67% the first 9 days. 
 
Citalopram shows a low daily decrease in both the S. marinoi and the second A. longicornis 
experiment in the average measured concentrations of 0.57% (day 1 to day 14) and 0.27% 
(day 2 to day 16) respectably. Sertraline had a decrease in the average measured concentration 
of 3.93% in the S. marinoi experiment and 4.88% in the second A. longicornis experiment. 
 
In a mete-analysis conducted by Webb et al (12) it was stated that fluoxetine and fluvoxamine 
were 10 of the most acute toxic pharmaceuticals. The Stockholm County Council (9) 
concludes with fluoxetine being a low environmental risk and fluoxetine being an 
insignificant environmental risk in the aquatic environment. In this study there is an almost 
complete degradation of both fluoxetine and fluvoxamine in both experiments, which may 
indicate that they have a low or an insignificant environmental risk in the aquatic environment 
even though they have been shown to have acute toxic effects. 
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Citalopram had a stable average measured concentration in both experiments, with low 
degradation. The Stockholm County Council (9) does not have sufficient documentation to 
draw a conclusion about the environmental risk for citalopram in the aquatic environment. 
One cannot conclude from this study any environmental risk factor for citalopram. 
 
In an environmental risk assessment study conducted by Styrishave et al (13) they looked at 
cocktail effect exposure of sertraline, citalopram and fluoxetine. It was concluded with 
sertraline being the most toxic of the three SSRIs, and was the most likely to contribute to a 
cocktail effect after STP degradation. The Stockholm County Council (9) concludes with 
sertraline being a moderate environmental risk. The degradation of sertraline is not complete 
for any of the experiments in this study, so one can only assume that the same grade of 
degradation is a possible scenario in a marine environment. In that case, there is a possibility 
of sertraline being a moderate environmental risk. It would be of interest to investigate this 
closer. 
 
Diatoms may release allelopathic compounds as a biochemical defense mechanism. They are 
also in need of nutrients and have pores and enzymatic pathways in order to retrieve the 
nutrients the need. It might be possible that either these allelopathic compounds or that they 
may have used the SSRIs as nutrients may have been factors in the decreasing average 
measured concentrations of the SSRIs.  
 
An interesting perspective is the fact that Norway is traditionally a maritime nation, where 
export of fish is a large, important industry for the country. It is important that we, through 
our own research, keep an international credibility in our knowledge about the influence 
pharmaceuticals and other pollutants have on the environment. We need to be able to confirm 
or disprove the claims that international press make from time to time, that will directly affect 
or export market. 
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4. Conclusion and Further Perspectives 
This thesis showed that there was a difference in degradation of the SSRIs between the two 
monocultures of S. marinoi and A. longicornis. The experiment containing the diatom S. 
marinoi had a higher decrease in the average measured concentration for fluoxetine, 
fluvoxamine, paroxetine and citalopram than the A. longicornis experiments. Fluoxetine and 
fluvoxamine were the least stable SSRIs. For the first 7 days of the S. marinoi experiment, 
fluoxetine had a decrease of 95%, while fluvoxamine had a decrease of 99.5%, while 
fluvoxamine had a decrease of 87% from day 2 to day 9, in the A. longicornis experiment.  
 
The Stockholm County Council classifies Sertraline as a moderate environmental risk, which 
is the highest environmental risk given to any of the SSRIs. In this study sertraline had a 
slower degradation in the average measured concentration compared to fluoxetine and 
fluvoxamine, but it was not as stable as Citalopram. 
 
LPME was used for the extraction and up concentration of the SSRIs, while UPLC-MS/MS 
with an MRM method was used for detection and quantification. These methods are well 
suited for the extraction and quantification of SSRIs from seawater containing algae and 
growth media.  
 
For a further perspective, one should optimize the MRM method used in this experiment by 
giving the SSRIs and metabolites their own “time window” in the method. This would 
increase the sensitivity of the method. One should also analyze the samples on a UPLC 
coupled to a quadrupole time of flight mass spectrometer. This would help identify more 
compounds in the sample, for example other metabolites and degradation products. 
 
In order to asses the consequences pharmaceuticals have on diatoms, it would be interesting to 
look at how diatoms initially react to pharmaceuticals, if they consume them in any way, and 
if so, to also look at possible metabolizing pathways. But since there is an estimate of more 
than 200,000 different species of diatoms, this will be difficult to for each and every one.  
 
There is a need for studies that look at degradation of pharmaceuticals and their metabolites in 
the environment, and the possible uptake of these in aquatic organisms. Not only for separate 
pharmaceuticals, but one should also take into account the possibility for “cocktail effects”. 
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Bioaccumulation and biomagnification of pharmaceuticals in food webs should also be looked 
into.  
 
Very few countries have publications or databases that can give statistics on drug 
consumption, and therefore there are no available data on the total amount of pharmaceuticals 
used in the world, and the consumption of pharmaceuticals differ form country to country. 
A model for worldwide pharmaceutical use and how these pharmaceuticals end up in the 
marine environment is needed. 
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The composition of earth extract and silicate solution. 
 
Table 15: The composition of earth extract 
Earth extract Amount 





Table 16: The composition of silicate solution 
Silicate solutin Amount 
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Appendix 2 
Table 17 shows the parameters used in the mass spectrometer. 
 
 
Table 17: Parameters for the mass spectrometer. 
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Appendix 3 
Parameters for the TargetLynx method are shown in Table 18 through Table 34. 
 












Table 21: Parameters for the TargetLynx metod. 
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Table 25: Parameters for smoothing and baseline noise. 
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Table 29: Threshold parameters 
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Table 33: Noise parameters and signal level measure. 
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Appendix 4 
Calibration curves for each SSRI is shown in Figure 62-Figure 70. The peak area ratio 
between the reference standards (AUC) and the internal standards (IS AUC) is given on the y-
axis, while the concentration (ng/L) is given on the x-axis. The formula for the regression line 
(y=mx+b) and the regression constant (R2) is also shown. 
 
Figure 62: The calibration curve for Sertraline.  
 
Figure 63: The calibration curve for Desmethylsertraline. 
 
Figure 64: The calibration curve for Fluoxetine  
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Figure 66: The calibration curve for Fluvoxamine.  
 
Figure 67: The calibration curve for Psroxetine. 
 
Figure 68: The calibration curve for Citalopram  Figure 69: The calibration curve for 
Desmethylcitalopram. 
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Appendix 5 
Examples of chromatograms of the substral growth medium for all the precursor ions of the 
SSRIs and the fragment ions used in the TargetLynx-method detected with an MRM-method 
are shown in 
 
Figure 71: Chromatogram of the substral growth medium for rac-trans-paroxetine D4, paroxetine, citalopram D6, 
citalopram, fluvoxamine and desmethylcitalopram. 
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Figure 72: Chromatogram of the substral growth medium for fluoxetine D5, fluoxetine, sertraline D3, sertraline, 
didesmetylciralopram, norfluoxetine and desmethylsertraline. The red circle indicates the peak for 
didesmethylcitalopram. 
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Appendix 6 
 
Table 35 shows the SSRIs and their average measured concentrations, standard deviation 
(SD), and relative standard deviation (RSD) by growth medium in the control experiment. 
 
Table 35: The average measured concentrations for each day test were taken, standard deviation (SD), and relative 
standard deviation (RSD) for each average. 
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Appendix 7 
Table 36 shows the average measured concentrations (ng/L) for each SSRI for each sampling 
day in the S. marinoi experiment. Standard deviation (SD) and realtive standard deviation 
(RSD) in % are also given. 
  
Table 36: The average measured concentrations (ng/L) for each SSRI for each sampling day in the S. marinoi 
experiment. Standard deviation (SD) and relative standard deviation (RSD) in % is also given.1 
 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  -: no liquid from the fiber thread 
  *: no signal from the MS/MS 
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Appendix 8 
Table 37 shows the average measured concentrations for each SSRI for each sampling dag 
and parallel in the first A. longicornis experiment. Standard deviation (SD) and relative 
standard deviation (RSD) is also given 
 
Table 37: The average measured concentrations for each SSRI for each sampling day in the first A.longicornis 
experiment. Standard deviation (SD) and relative standard deviation (RSD) in % is also given. 
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Appendix 9 
Table 38 shows the average concentrations for each SSRI for each sampling dag and parallel 
in the second A. longicornis experiment. Standard deviation (SD) and relative standard 
deviation (RSD) is also given.2 
 
Table 38: The average concentrations for each SSRI for each sampling day in the second A.longicornis experiment. 
Standard deviation (SD) and relative standard deviation (RSD) in % is also given. 
 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 -: no liquid from the fiber thread 
  *: no signal from the MS/MS 
 #: not able to calculate RSD % beacuse of no SD avilable	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Appendix 10 
Table 39 shows the measured Ra- and Rb-values for the S. marinoi experiment. These values 
are used further on to calculate the Chl a and the phaeophytine values in using formulas 2.1 
and 2.2. 
 




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  -: Did not measure Ra before adding 10% HCl.	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Table 40: The calculated Chl a and phaeopytine values for the S. marinoi experiment. 
Date samples taken 03.03.14 10.03.14 17.03.14 
Date samples 
measured 04.03.14 11.03.14 18.03.14 
Beaker 1    µg Chla/L 2.34 8.20 2.04 
µg Phaeo/L 1.12 4.53 2.99 
Beaker 2    
µg Chla/L 2.25 6.81 6.01 
µg Phaeo/L 1.14 4.31 8.86 
Beaker 3    µg Chla/L 1.74 7.07 11.26 
µg Phaeo/L 1.11 5.09 8.62 
Control    
Date samples taken 09.03.14 16.03.14 20.03.14 
Date samples 
measured 10.03.14 17.03.14 21.03.14 
µg Chla/L 1.22 1.12 44.55 
µg Phaeo/L 0.89 3.97 16.99 
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Appendix 11 
Table 41 shows the measured Ra- and Rb-values for the first A. longicornis experiment. 
These values are used further on to calculate the Chl a and the phaeophytine values in Table 
42 using formulas 2.1 and 2.2. 
 
Table 41: Measured Ra- and Rb-values for the first A. longicornis experiment. 
Date samples taken 11.03.14 18.03.14 24.03.14 
Date samples measured 12.03.14 19.03.14 25.03.14 
Ra-values µg/L µg/L µg/L 
Beaker 1, Parallel 1 22.50 5.10 173.70 
Beaker 1, Parallel 2 10.70 5.60 179.40 
Beaker 1, Parallel 3 19.80 5.80 154.50 
Average, Beaker 1 17.67 5.50 169.20 
Beaker 2, Parallel 1 20.90 4.80 158.20 
Beaker 2, Parallel 2 19.00 4.10 177.00 
Beaker 2, Parallel 3 21.40 4.50 167.80 
Average, Beaker 2 20.43 4.47 167.67 
Beaker 3, Parallel 1 17.20 5.10 145.60 
Beaker 3, Parallel 2 17.90 5.70 148.10 
Beaker 3, Parallel 3 16.80 4.90 143.00 
Average, Beaker 3 17.30 5.23 145.57 
Control, Parallel 1 14.50 4.20 63.40 
Control, Parallel 2 12.80 4.60 58.40 
Control, Parallel 3 14.90 3.50 59.90 
Average, Control 14.07 4.10 60.57 
Rb-values µg/L µg/L µg/L 
Beaker 1, Parallel 1 12.20 2.90 91.50 
Beaker 1, Parallel 2 5.30 3.20 93.10 
Beaker 1, Parallel 3 10.80 3.10 80.80 
Average, Beaker 1 9.43 3.07 88.47 
Beaker 2, Parallel 1 12.00 2.70 82.80 
Beaker 2, Parallel 2 10.60 2.30 91.30 
Beaker 2, Parallel 3 12.30 2.70 91.40 
Average, Beaker 2 11.63 2.57 88.50 
Beaker 3, Parallel 1 9.40 2.90 77.00 
Beaker 3, Parallel 2 9.70 3.30 76.60 
Beaker 3, Parallel 3 9.50 2.70 79.30 
Average, Beaker 3 9.53 2.97 77.63 
Control, Parallel 1 7.30 2.60 32.00 
Control, Parallel 2 7.00 2.80 29.30 
Control, Parallel 3 7.70 2.30 30.80 
Average, Control 7.33 2.57 30.70 
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Table 42: The calculated Chl a and phaeopytine values for the first A. longicornis experiment.  
Date samples taken 11.03.14 18.03.14 24.03.14 
Date samples 
measured 12.03.14 19.03.14 25.03.14 
Beaker 1 
   µg Chla L-1 2.83 1.67 55.53 
µg Phaeo L-1 0.77 0.67 12.01 
Beaker 2 
   µg Chla L-1 3.03 1.31 54.45 
µg Phaeo L-1 1.41 0.65 13.12 
Beaker 3 
   µg Chla L-1 2.67 1.56 46.72 
µg Phaeo L-1 0.97 0.71 12.55 
Control    
µg Chla L-1 2.32 1.05 102.71 
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Appendix 12 
Table 43 shows the measured Chl a and phaephytine values for the second A. longicornis 
experiment.  
 
Table 43: Measured Chl a and phaeophytine values for the second A. Longicornis experiment4. 
Date samples taken 01.04.14 07.04.14 15.04.14 
Date samples measured 02.04.14 08.04.14 16.04.14 
Chl a µg/L µg/L µg/L 
Beaker 1, Parallel 1 2.21 3.70 9.56 
Beaker 1, Parallel 2 2.20 3.87 9.36 
Beaker 1, Parallel 3 2.20 3.53 11.84 
Average, Beaker 1 2.20 3.70 10.25 
Beaker 2, Parallel 1 1.70 3.50 7.37 
Beaker 2, Parallel 2 1.65 3.90 10.44 
Beaker 2, Parallel 3 2.51 3.66 12.14 
Average, Beaker 2 1.95 3.69 9.98 
Beaker 3, Parallel 1 2.54 5.16 16.62 
Beaker 3, Parallel 2 1.95 4.48 13.67 
Beaker 3, Parallel 3 2.93 4.71 8.41 
Average, Beaker 3 2.47 4.78 12.90 
Control, Parallel 1 3.21 6.54 15.68 
Control, Parallel 2 2.69 6.61 16.09 
Control, Parallel 3 2.66 7.13 10.93 
Average, Control 2.85 6.76 14.23 
Phaephytine µg/L µg/L µg/L 
Beaker 1, Parallel 1 * 1.63 0.40 
Beaker 1, Parallel 2 0.10 0.84 2.21 
Beaker 1, Parallel 3 0.12 0.24 0.33 
Average, Beaker 1 0.11 0.90 0.98 
Beaker 2. Parallel 1 0.13 * * 
Beaker 2. Parallel 2 0.70 * 1.02 
Beaker 2. Parallel 3 * * 2.88 
Average. Beaker 2 0.42 0 1.95 
Beaker 3, Parallel 1 * 0.59 * 
Beaker 3, Parallel 2 * * * 
Beaker 3, Parallel 3 * * * 
Average, Beaker 3 0 0.59 0 
Control, Parallel 1 * 0.37 0.89 
Control, Parallel 2 * * * 
Control, Parallel 3 0.24 * 3.71 
Average, Control 0.24 0.37 2.30 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4	  *: Negative values for the phaephytine measurents. This means that the cells are in the beginning of a growth-
phase.	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